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1 Introduction 
In the 19th century, Robert Koch identified the microorganisms causing anthrax, tuberculosis 
and cholera and deduced that each infectious disease is caused by a specific 
microorganism. In our daily live, we are surrounded by a multitude of different 
microorganisms – some of them are pathogenic, some are not. The immune system has to 
discriminate between harmful and harmless microorganisms and agents. Evolutionary, 
various mechanisms of the innate and the adaptive immunity have been evolved to 
recognize and to protect the organism against pathogens, but at the same time sustain 
immune homeostasis, thus preventing allergic reactions or auto-immunity against self-
antigens. 
The innate immunity comprises first line defense properties such as epithelial barriers, 
antimicrobial peptides and enzymes and special soluble plasma peptides that build the 
complement system. Once microorganisms overwhelm the first line barriers, they are 
recognized by tissue resident phagocytic cells like monocytes, macrophages, granulocytes 
and dendritic cells (DC). By presenting processed antigens to T cells, DC link innate to 
adaptive immunity. In contrast to the innate immune functions, adaptive immune responses 
develop over lifetime as specific reactions to certain pathogens (adaption). The major cell 
types of the adaptive immunity, the T and B lymphocytes, are endowed with an enormous 
repertoire of highly specialized receptors. Once a pathogen has been recognized, an 
immunological memory is generated which protects an individual from reinfections with the 
hence known agent. 
 
1.1 Dendritic cells  
“The cytoplasm of this large cell is arranged in pseudopods of varying length, width, form 
and number, resulting in a variety of cell shapes ranging from bipolar elongate cells to 
elaborate, stellate or dendritic ones. […] The term “dendritic” cell would thus be appropriate 
for this particular cell type.”, wrote Ralph Marvin Steinman in 1973 when he and his 
colleagues first described murine splenic DC (Steinman and Cohn 1973). 
Since the DC discovery, substantial research concerning their ontogeny and development, 
their heterogeneity, their sources in the body and their function, especially in mice, was 
performed. Although human material is more difficult and less frequently available than the 
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murine counterpart, recently efforts were increased to investigate the human DC system. 
This elucidates human and mouse homologues as well as differences between the species. 
 
1.1.1 DC ontogeny 
During the last decades, it became apparent that human DC arise from myeloid and from 
lymphoid progenitors or even so called multi-lymphoid progenitors (Chicha et al. 2004, 
Doulatov et al. 2010), which may give rise to lymphoid as well as myeloid cell types like DC. 
Recent studies affirmed and complemented that human DC arise from CD34+ hematopoietic 
stem cells through a series of lineage-determining progenitors (Lee et al. 2015). In the 
course of a sequential differentiation, granulocyte-monocyte-DC progenitors (hGMDP) 
develop into human monocyte-dendritic progenitors (hMDP), which have restricted potential 
to become monocytes or committed DC progenitors (CDP) (Lee, Breton et al. 2015). CDP 
give rise to plasmacytoid DC (pDC) and to circulating pre-DC precursors, which are released 
into the blood and differentiate into the myeloid CD1c+ DC and CD141+ DC subsets in the 
respective tissues (Breton et al. 2015). The first assumption was that those myeloid DC 
(mDC) subsets develop from one unique pre-CDC precursor, but current studies uncovered 
two distinct pre-CDC precursors for each mDC subtype (Breton et al. 2016). 
DC development and differentiation is promoted by a set of transcription factors like runt-
related transcription factor 1 (Runx1), PU.1 (Schotte et al. 2004), Spi-B (Schotte, Nagasawa 
et al. 2004), Batf3 (Poulin et al. 2012), Irf-4, Irf-8 (Hambleton et al. 2011, Salem et al. 2014, 
Schiavoni et al. 2002, Tsujimura et al. 2003), Id2, E2-2 (Nagasawa et al. 2008) as well as by 
the hematopoietins fms like tyrosine kinase 3 ligand (FLT3L) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Kingston et al. 2009, Maraskovsky et al. 2000) whose 
signaling is mediated by the signal transducer and activator of transcription 3 (STAT3) and 
STAT5, respectively (reviewed in (Chicha, Jarrossay et al. 2004, Collin et al. 2013, Haniffa 
et al. 2015)). In contrast, Langerhans cells (LC), a skin- and mucosal-restricted DC subtype, 
develop independently from FLT3L and require macrophage colony-stimulating factor (M-
CSF), STAT5 and transforming growth factor beta 1 (TGF-β1).  
In vitro, human DC can be generated from blood monocytes as well as from bone marrow or 
umbilical cord blood-derived CD34+ hematopoietic stem cells by feeding a combination of 
GM-CSF and IL-4 (Bender et al. 1996, Sallusto and Lanzavecchia 1994) and TNF-α, 
respectively (Caux et al. 1992, Caux et al. 1996). For in vitro generation of LC from CD34+ 
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hematopoietic stem cells, TGF-ß1 is strictly required (Strobl et al. 1996). In this study, LC 
were generated in vitro from umbilical cord blood-derived CD34+ hematopoietic stem cells 
as described by Herrmann et al. (Herrmann et al. 2013).  
 
1.1.2 DC subsets 
Different subsets of human DC are classified based on their ontogeny (myeloid, 
plasmacytoid), their phenotype (i.e. expression of blood dendritic cell antigens, BDCA 
(Dzionek et al. 2000)) or their spatial distribution (tissues, lymph nodes, blood). Most 
commonly, DC are divided into two main subgroups: the myeloid and the plasmacytoid DC 
(reviewed in (Collin, McGovern et al. 2013, Guilliams et al. 2014, Ziegler-Heitbrock et al. 
2010)). The two main groups are accompanied by further subtypes such as monocyte-
derived DC, migratory dermal CD14+ DC, epidermal Langerhans cells (LC) as well as 
inflammatory dendritic epidermal cells (IDEC) and TNF-α and inducible nitric oxide synthase 
(INOS) -producing DC (Tip-DC).  
Regardless of their subtype, DC are characterized by their high expression of major 
histocompatibility complex (MHC) class II molecules and lack the lymphoid lineage-specific 
markers CD3, (T cells), CD19/CD20 (B cells) and CD56 (natural killer cells, NK) (reviewed in 
(Collin, McGovern et al. 2013, Ziegler-Heitbrock, Ancuta et al. 2010)).  
Below, human DC subtypes will be summarized in short by their most commonly accepted 
descriptive and functional classifications.  
 
1.1.2.1 Myeloid DC 
Myeloid DC correspond to the murine “classical” or “conventional” termed DC. They express 
myeloid lineage-associated antigens CD13 and CD33 (Siglec-3, sialic acid binding Ig-like 
lectin 3) as well as the integrins CD11b and CD11c, but no CD14 or CD16 (FcγRIII). Myeloid 
DC can be further split into CD1c+ DC (BDCA-1+) and CD141+ DC (BDCA-3+).  
Myeloid CD1c+ DC represent the major DC population and are found in the blood, in 
epithelial tissues and in lymphoid organs. They sense different microbial antigens via a set 
of pattern recognition receptors like TLR1, TLR2, TLT4, TLR5 and TLR8 (summarized in 
(Haniffa, Bigley et al. 2015). The expression of CD1c and CD1a (restricted to tissue DC) 
enables CD1c+ DC to process glycolipid antigens of pathogens like mycobacteria (Hunger et 
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al. 2004, Van Rhijn et al. 2013). Further on, CD1c+ DC are endowed with the C-type lectins 
Dectin-1 (CLEC7A) and Dectin-2 (CELC6A) promoting fungal recognition (Ariizumi et al. 
2000, Drummond and Brown 2011, McGreal et al. 2006) as well as CD205 (DEC-205) and 
CD206, which allow them to recognize mannose residues of bacterial cell envelopes. 
Dependent on the stimuli, activated CD1c+ DC secrete the interleukins IL-8, IL-10, IL-12p70 
and in part IL-23 (Morelli et al. 2005). They are potent stimulators of naïve T cells and are 
able to promote T helper cells 1 (TH1), TH2 and TH17 responses (reviewed in (Collin, 
McGovern et al. 2013, Haniffa, Bigley et al. 2015)). 
A second myeloid DC type are the CD141+ DC which find their murine homologue in CD8+ 
DC and represent only 0.05 % of the human peripheral blood lymphocytes. Depending on 
certain conditions, the expression of CD141 (thrombomodulin) can also be found on 
migratory DC and CD1a+ DC. In addition, myeloid CD141+ DC can be distinguished from 
other CD141+ DC by their lower expression of CD11b and CD11c. In comparison to other 
DC subtypes, CD141+ DC are superior in the presentation of exogenous antigens via MHC 
class I molecules (cross-presentation) to naïve cytotoxic CD8+ T cells. CD141+ DC are able 
to take up dead or necrotic cells via CLEC9A, a recently discovered C-type lectin that is 
supposed to be only expressed on the CD141+ subtype (Schreibelt et al. 2012). Through 
TLR3 and TLR8 expression, CD141+ DC sense self or viral nucleic acids. Upon activation, 
CD141+ DC secrete TNF-α, the C-X-C motif chemokine 10 (CXCL10) and the type III 
interferon IFN-λ. They polarize CD4+ T cells to TH2 (reviewed in (Collin, McGovern et al. 
2013, Haniffa, Bigley et al. 2015)). 
 
1.1.2.2 Plasmacytoid DC (pDC) 
Initially, pDC were termed due to their plasma cell-like morphology and their inherent ability 
of immunoglobulin gene rearrangements (Colonna et al. 2004, Rissoan et al. 2002). They 
represent the most numerous DC circulating in the blood and can also be found in the lymph 
nodes, but are not abundant in healthy tissues (Ebner et al. 2004, Zaba et al. 2007). They 
can be distinguished from other DC subtypes by the low or even lacking expression of the 
myeloid lineage-associated markers CD11b, CD11c, CD13 and CD33 and the expression of 
CD123 (IL-3 receptor, IL-3R), CD303 (CLEC4C, BDCA-2) and CD304 (neutropilin, BDCA-4). 
In response to viral nucleic acids sensed by TLR7 and TLR9, pDC secret large amounts of 
type I interferons (Cella et al. 1999, Siegal et al. 1999). pDC may induce TH1, TH2 (Rissoan 
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et al. 1999) and regulatory T cell (Treg) differentiation (Moseman et al. 2004) and are able to 
cross-present exogenous antigens to CD8+ T cells (Hoeffel et al. 2007). 
 
1.1.2.3 Skin DC 
Human skin DC represent a first cellular defense for invading microorganisms which 
overcame the epithelial barrier of the skin. They are involved in bridging innate and adaptive 
immunity by presenting antigens to T cells of skin-draining lymph nodes, but also in keeping 
homeostasis by inducing tolerance (Novak and Bieber 2008, Novak et al. 2004). In non-
inflamed skin, epidermal LC, mDC and CD14+ dermal DC, recently discussed as monocyte-
derived macrophages by virtue of their transcriptional profile (McGovern et al. 2014), can be 
found. During inflammation, the composition of DC subsets is changing and pDC, LC and 
IDEC are selectively recruited to the site of inflammation (Wollenberg et al. 2002).  
 
1.1.2.4 Langerhans cells 
In 1868, the medical student Paul Langerhans discovered a dendrite-shaped cell in the 
human epidermis. In Virchows Archiv: The European Journal of Pathology, he stated the 
question of a stromal or nerve cell origin of those special cells. Because of their alternating 
number of dendrites, he assumed that those cells were cells of the nervous system 
(Langerhans 1868). More than 100 years later, it was apparent that the young student 
unknowingly was the first one to describe a dendritic cell subset of the epidermis that was 
later named after his discoverer Paul Langerhans.  
Up to date numerous research results shed light on the distribution, the development and 
the function of LC in mice and more recently in human, too. As described by Paul 
Langerhans, the morphology of LC is characterized by a various number of dendrites of 
variable length and shape, which are more pronounced in the mature LC phenotype. A 
hallmark of LC is the expression of Birbeck granules, discovered by Michael Birbeck in 1961 
(Birbeck et al. 1961). Birbeck granules are tennis-racket-shaped cell organelles formed by 
the C-type lectin Langerin (CD207) (Valladeau et al. 2003, Valladeau et al. 2000). Today, 
Langerin is the most prevalent marker to identify LC populations and antibodies against 
Langerin replaced the formerly used Birbeck granule-detecting Lag antibody that most likely 
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detects a Langerin epitope within the Birbeck granule (Kashihara et al. 1986, Valladeau, 
Ravel et al. 2000).  
LC are located in the supra-basal layer of the epidermis as well as in various mucosae of 
the body like nasal and oral mucosae (Allam et al. 2006) or those of the intestine (reviewed 
in (Romani et al. 2010)). In steady-state, LC represent 2-5 % of the epidermal cells in adults. 
Additionally, LC can be found in the paracortex of human skin-draining lymph nodes (Angel 
et al. 2009). More than a half of the LC found in the lymph nodes typically show a mature 
phenotype indicating a preceding inflammatory process.  
As opposed to the case with other DC, LC homeostasis in undisturbed skin is sustained by 
the self-renewing capability and the longevity of the cells (Kanitakis et al. 1993). This was 
shown in a patient receiving a hand graft by the fact that LC from the donor could be found 
for more than four years in the graft’s skin (Kanitakis et al. 2004). Moreover, mice 
experiments have shown that recruited monocytes can give rise to LC to repopulate the skin 
after inflammation-induced LC emigration (Ginhoux et al. 2006). In contrast to DC, LC can 
develop independently of FLT3L, but are strictly TGF-ß1-dependent as shown in TGF-ß1 
knock-out mice that do not develop LC (Borkowski et al. 1996). Moreover, knock-out of the 
TGF-ß1 downstream transcription factors Id2 and Runx3 abolished LC development, too 
(summarized in (Romani, Clausen et al. 2010)). TGF-ß1 is secreted by the LC themselves 
supporting the self-renewal capacity in an autocrine way (Kaplan et al. 2007). In vitro, 
human LC can be generated from CD34+ hematopoietic progenitors in the presence of 
FLT3L, stem cell factor (SCF), GM-CSF and TGF-ß1 (Strobl, Riedl et al. 1996). 
In line with other DC, LC take up antigens by a numerous set of pattern recognition 
receptors (PRR) like Toll-like receptor 2 (TLR2) heterodimers and TLR4 (Novak et al. 2010). 
Activated LC migrate to skin draining lymph nodes and present the antigen/MHC complex to 
naïve T cells. Notably, LC are able to cross-present exogenous antigens and efficiently drive 
CD8+ cells to become cytotoxic effector T cells (Klechevsky et al. 2008). Depending on the 
maturation state, the antigen and the given microenvironment, LC are described not only to 
induce immunity, but also tolerance, i.e. by negatively regulating T cell proliferation 
(Shklovskaya et al. 2011) or by the production of the immunoregulatory enzyme indoleamine 
2,3-dioxygenase (IDO) (von Bubnoff et al. 2004) and the TH1 anergy inducing IL-10 (Enk et 
al. 1993).  
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1.1.2.5 Inflammatory dendritic epidermal cells (IDEC) 
In inflamed skin, a DC population was found which appears morphologically (dendrite- 
shaped), phenotypically (CD1a+, HLA-DR+,FcεRI+) and locally (epidermal) similar to LC, but 
was strictly distinct from classical LC by the lack of Birbeck granules and the expression of 
the mannose receptor DC206 and the integrins CD11b and CD11c (Wollenberg et al. 1996, 
Wollenberg, Mommaas et al. 2002). Those DC were termed inflammatory dendritic 
epidermal cells (IDEC) and could be found in most inflammatory skin conditions like atopic 
dermatitis (AD) and psoriasis vulgaris. In vitro, IDEC can be generated under reducing 
conditions from monocytes of atopic donors (Novak et al. 2002). 
 
1.1.2.6 TNF-α and INOS-producing DC (Tip-DC) 
In contrast, TNF-α and INOS-producing DC (Tip-DC) can be found in the context of 
psoriasis vulgaris and are located in the dermis as well as the epidermis. Tip-DC belong to 
the myeloid CD11c+ DC population and express typical DC markers such as HLA-DR, 
CD40, CD83 and CD86, but lack Langerin, CD1a and CD14 antigens. As indicated by their 
name, Tip-DC are potential mediators of inflammation by the release of TNF-α and INOS 
(Lowes et al. 2005, Serbina et al. 2003, Wilsmann-Theis et al. 2013).  
 
1.1.3 DC function 
Immature DC sense and take up antigens by different receptor-dependent mechanisms 
including mannose receptor-mediated endocytosis of mannosylated microbial protein 
antigens (Wollenberg, Mommaas et al. 2002) or FcγRII-mediated internalization of antigen-
receptor complexes (reviewed in (Nimmerjahn and Ravetch 2007)). Antigen-uptake and 
internalization is often accompanied by DC maturation. During this process, DC undergo a 
series of phenotypical and functional alterations such as the upregulation of surface MHC 
class II molecules and the co-stimulatory molecules CD40, CD80, CD86 and CD83. 
Additionally, migratory capacities increase due to the upregulation of the CCRX chemokine 
7 receptor (CCR7). During their maturation, DC almost lose their phagocytic properties, but 
gain their T cell priming capability. 
8 Introduction 
In general there are two ways of antigen presenting via MHC molecules depending on the 
nature of the antigens. Intracellular antigens including self-proteins are normally degraded 
proteasomally and assemble with MCH class I molecules in the endoplasmic reticulum 
before the complex is transported to the DC’s surface for recognition by CD8+ T cells. In 
contrast, extracellular antigens are processed and loaded on MHC class II molecules in late 
endosomal compartments. Antigen/MHC class II complexes are recognized by CD4+ T cells 
(reviewed in (Blum et al. 2013)). In some DC subsets including LC, exogenous antigens 
might be presented by MHC class I complexes. This so called cross-presentation enables 
antigen presenting cells (APC) to present exogenous antigens to CD8+ T cells and induce 
either immunity (i.e. in the case of pathogens) or tolerance against self-antigens by 
peripheral deletion of autoreactive CD8+ T cells (Kurts et al. 2001). 
The kind of antigen, its dose and the duration of contact in a given environment may induce 
the processing pathway and select the MHC, but the T cell response leading to either 
immunity or tolerance is dictated by a series of co-stimulatory and accessory molecules and 
signals. The first of three signals determining the T cell fate is the binding of the T cell 
receptor (TCR) to the respective antigen/MHC complex. Standing alone, signal 1 promotes 
tolerance by provoking anergy or deletion of the respective naïve T cell (Wang et al. 2002). 
The second signal encompasses co-stimulatory molecules consisting of receptors of the 
APC and its respective ligand on the T cell. DC express CD80/CD86 (B7.1/B7.2) for CD28 
binding that results in IL-2 production and subsequent T cell proliferation, while the binding 
of the anti-proliferative cytotoxic T-lymphocyte antigen 4 (CTLA-4) leads to peripheral 
tolerance (Probst et al. 2005). Moreover, the absence of CD80/CD86 on the DC leads to 
anergy and deletion of the respective T cell. Third, the fate of a T cell to develop into TH1, 
TH2 or into cytotoxic T cells (CTL) is dictated by the expression of TH cell-polarizing 
molecules such as IL-12 family members, type I interferons or TGF-ß for TH1 priming or the 
C-C motif ligand 2 (CCL2; also known as monocytic chemotactic protein 1 (MCP1)) and 
OX40 ligand for TH2 development (reviewed in (Kapsenberg 2003)).  
 
1.1.4 The role of DC in atopic dermatitis 
Atopic dermatitis (AD) is a multifactorial chronic relapsing skin disease with increasing 
incidence in western industrialized countries. The disease usually starts in the early 
childhood and is often the beginning of the so called atopic march that is followed 
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characteristically by allergic rhinitis or allergic asthma (reviewed in (Bieber 2008)). One 
hallmark of the disease is a genetically predisposed impairment of epidermal barrier 
functions which facilitate the entrance of foreign antigens into skin compartments, where 
they can activate resident DC (reviewed in (Novak 2012)).  
Unlike LC, which are present in healthy and infected skin, IDEC are restricted to inflamed 
skin only. In contrast to other skin diseases like psoriasis vulgaris or contact dermatitis, the 
amount of pDC in dermal AD skin is controversially discussed varying from absent 
(Wollenberg et al. 2002) to substantial numbers (Guttman-Yassky et al. 2007). However, 
diminished pDC expression in AD may explain the enhanced susceptibility for viral infections 
like the herpes simplex -induced eczema herpeticum (Wollenberg, Wagner et al. 2002).  
Both IDEC and LC, but not pDC, express CD1a which mediates the presentation of lipid 
antigens to T cells (reviewed in (Mizumoto and Takashima 2004)). Additionally, skin DC in 
AD are equipped with a particular set of intra- and extracellular TLR. TLR2 is expressed by 
epidermal LC as well as dermal DC (reviewed in (Novak, Koch et al. 2010)). For ligand 
binding, TLR2 forms heterodimers with TLR1 and TLR6 (Biedermann 2006). TLR1/2 
heterodimers recognize triacylated lipopeptides like Pam3Cys-Ser-(Lys)4 (P3C) (Buwitt-
Beckmann et al. 2006) while TLR2/6 heterodimers interact with diacylated lipopeptides such 
as Pam2CGDPKHPKSF (FSL-1) (Skabytska et al. 2014). In vivo, TLR2 heterodimers are 
described to bind bacterial peptidoglycans like from the Gram-positive bacterium 
Staphylococcus aureus (S.a.) , which predominantly colonizes the skin of AD patients 
(Boguniewicz and Leung 2010). In contrast, TLR4 represents the main structure in 
recognizing lipopolysaccharides (LPS) of Gram-negative bacteria. Human skin LC, but not 
oral and mucosal LC, are described to lack TLR4 expression and do not respond to LPS 
(Allam et al. 2008, Flacher et al. 2006, van der Aar et al. 2007). Controversially, unpublished 
results of our group showed that ex vivo skin LC of healthy individuals are responding to 
LPS (personal communication Tim Stroisch). However, TLR-mediated activation of DC 
usually drives them to leave the skin towards skin-draining lymph nodes for antigen 
presentation and T cell priming. Thereby, the particular microenvironment, the dose, the 
exposure duration and the type of invading pathogens dictate the T cell developmental 
direction towards TH1, TH2 or Treg (Fujita et al. 2011).  
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1.2 The high-affinity receptor for IgE, FcεRI 
A hallmark of skin DC of atopic individuals is the expression of the high-affinity receptor for 
IgE, FcεRI ((Bieber et al. 1992) and reviewed in (Bieber 2008)). FcεRI is a multimeric 
immune receptor existing in a tetrameric and a trimeric form. The tetrameric receptor 
consists of one α-chain for IgE binding, one ß-chain with signal amplifying and stabilizing 
functions (Lin et al. 1996) and two γ-chains for signal transduction. The ß-chain and the γ-
chains contain intracellular immunoreceptor tyrosine-based activation motifs (ITAM) which 
are phosphorylated after cross-linking of the receptor and induce the downstream signaling. 
The γ-chain is shared by other Fc receptors like FcγRI and FcγRII. In mice and humans, the 
tetrameric form is expressed on mast cells and basophiles. In contrast, the ß-chain lacking 
trimeric form is restricted to human APC like DC and LC (Bieber, de la Salle et al. 1992, 
Kinet 1999). Rodents do not express FcεRI on DC. In AD, the trimeric FcεRI (αγ2) shows a 
heterogeneous and higher expression on LC and especially on IDEC compared to skin DC 
from healthy individuals (Herrmann, Koch et al. 2013, Jurgens et al. 1995, Wollenberg, Kraft 
et al. 1996). The high expression of the receptor correlates with serum IgE levels and the 
severity of the disease (Potaczek et al. 2014, Weidinger et al. 2008). Binding of monomeric, 
allergen-independent IgE stabilizes the receptor on the cell surface, while cross-linking of 
the receptor by specific allergen-bound IgE leads to internalization and subsequent 
processing of the allergen-IgE-FcεRI complexes by MHC class II compartments (Maurer et 
al. 1998). Allergen-derived antigens are presented to naïve T cells of skin-draining lymph 
nodes or locally to transiting antigen-specific T cells in the context of secondary immune 
responses. Thereby, TH2 responses are mainly induced by LC, while IDEC enhance pro-
inflammatory TH1-mediated INF-γ release (reviewed in (Novak and Bieber 2005)). This 
phenomenon explains why the initial phase of inflammation in AD skin is characterized by 
TH2 responses by skin resident LC, while the later phase switches to TH1 prevalence due to 
invading IDEC that occurs within 72 hours and is maintained in chronic AD (Kerschenlohr et 
al. 2003). Moreover, cross-linking of FcεRI on DC can induce the production of pro-
inflammatory cytokines such as TNF-α, IL-1ß or IL-8 and chemokines like CCL2 via the 
activation of nuclear factor-κB (NF-κB) (Kraft et al. 2002). More recently, FcεRI-mediated 
tolerogenic properties such as the release of the anti-inflammatory interleukin IL-10 (Novak 
et al. 2001) and the production of the immunoregulatory enzyme indoleamine, 2,3 
dioxygenase (IDO) (von Bubnoff, Bausinger et al. 2004, von Bubnoff et al. 2004) have been 
reported. Our former studies revealed that TLR-mediated activation of in vitro generated LC 
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results in a downregulation of FcεRI expression (Herrmann, Koch et al. 2013), thus 
influencing the course of AD by cross-talking of those receptors. 
FcεRI is transcriptionally regulated by two promotor elements. The proximal promotor is 
found in humans and rodents, while the distal promotor element is specific only for humans. 
The proximal promotor contains binding sites for two E26 transformation-specific (ETS) 
transcription factors, namely PU.1 (encoded by the SPI1 gene) and E74-like factor 1 (Elf-1), 
and for the GATA-binding factor 1 (Gata-1). Furthermore, transcription factor Yin-Yang-1 
(Yy1) shares an overlapping binding site with PU.1 and Elf-1 (see Figure 1) (Nishiyama, 
Hasegawa et al. 2002). Binding of PU.1 and Yy1 promotes FcεRIα transcription, while Elf-1 
acts inhibitory on the FcεRI promotor element by competing with PU.1 for the respective 
binding site (Wang et al. 2008). Gata-1 is required for FcεRI expression on mast cells, but is 
rather weakly expressed in LC (Herrmann, Koch et al. 2013, Nishiyama et al. 2005) 
compared to PU.1. Additionally, upstream of the PU.1/Elf-1/Yy1 binding region high mobility 
group box 1 and/or box 2 proteins (Hmgb1/Hmgb2) and the transcription factor Sp1 share a 
binding site in the promotor (see Figure 1). Which of those factors bind to the promotor 
sequence depends on the given single nucleotide polymorphism (SNP) in the binding 
region. Alleles promoting Hmgb1/2 binding reveal a stronger promotor activity compared to 
those that bind Sp1 (Kanada, Nakano et al. 2008).  
The distal promotor is IL-4-dependent. In contrast to the proximal promotor, the activity of 
the distal one is negatively regulated not only by Elf-1, but also by PU.1 and Yy1 (Hasegawa 
et al. 2003).  
 
Figure 1 Schematic representation of the FCER1A promotor. Positive regulators are depicted in blue; 
negative ones in red. Gata-1 (grey) is not expressed in CD34LC. (Adapted from (Kanada et al. 2008, Nishiyama 
et al. 2002)) 
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Among the FcεRI-associated transcription factors, PU.1 is stronger expressed in LC 
compared to Elf-1 and Yy1 and is regulated upon activation of the cells (Herrmann, Koch et 
al. 2013). In general, PU.1 is highly expressed in myeloid DC subsets and controls DC 
development inter alia by the regulation of the hematopoietic factor FLT3 (Carotta et al. 
2010). Similarly, PU.1 enhances LC development in concert with the TGF-ß1 responsive 
transcription factor Runx3 (Chopin et al. 2013, Heinz et al. 2006). To date, more than 100 
PU.1 target genes have been identified. Those are predominantly genes coding for 
extracellular or membrane-associated proteins such as antibodies and antibody receptors 
like FCER1A, FCER2 or genes for Fc gamma receptors (FCGR1A, FCGR2B, FCGR3A) 
(summarized in (Turkistany and DeKoter 2011)).  
Since a precisely regulated expression of PU.1 is crucial for normal hematopoiesis, several 
mechanisms exist for the control of PU.1 activity and expression. First, the PU.1 expression 
is transcriptionally regulated by the binding of tissue-specific transcription factors to the PU.1 
promotor. In myeloid cells, the transcription factors Sp1 and mainly PU.1 itself promote SPI1 
gene expression (Chen et al. 1995, Hoogenkamp et al. 2007). Additionally, distal regulatory 
elements upstream of the SPI1 gene promotor cooperate to induce PU.1 expression. 
Thereby, CCAAT/enhancer binding protein alpha (C/EBPα) opens the chromatin structure of 
the upstream regulatory element for autoregulatory PU.1 binding (Leddin et al. 2011). 
Secondly, protein interactions can influence the binding of PU.1 to a given promotor. 
C/EBPα plays a reciprocal role in PU.1 regulation. It physically inhibits the function of PU.1 
by displacing its co-activator c-Jun and thereby abolishes PU.1-induced DC development 
(Reddy et al. 2002). Furthermore, PU.1 function can be blocked by the interaction of the 
Gata-1 zinc finger domain with PU.1’s DNA-binding domain (Nerlov et al. 2000). Thirdly, 
post-transcriptional mechanisms can modulate PU.1 protein levels. Non-coding antisense 
RNA have been described to negatively regulate PU.1 gene expression through 
translational interference (Ebralidze et al. 2008). Another way to prevent the translation of 
mRNA transcripts into a functional protein is the binding of micro-RNA (miRNA). This will be 
the topic of the next section. 
 
1.3 micro-RNA in the immune system 
In the 1990, it was found that in Caenorhabditis elegans (C. elegans) a small RNA encoded 
by the lin-4 gene was able to suppress lin-14 protein expression by antisense 
complementarity to the gene’s 3’ untranslated region (3’ UTR) (Lee et al. 1993, Wightman et 
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al. 1993). A couple of years later, another small regulatory RNA, let-7, was discovered 
(Reinhart et al. 2000) and homologues of this small RNA were found in several other 
metazoan lineages including vertebrates, molluscs, annelids and arthropods (Pasquinelli et 
al. 2000). Nowadays, the term micro-RNA has been assigned to these special small (~ 22 
nucleotides, nt) regulatory RNA molecules.  
 
1.3.1 Origin of miRNA 
Primary miRNA precursor molecules (pri-miRNA) originate from independent genes or from 
intronic regions of protein-coding genes (Rodriguez et al. 2004, Saini et al. 2007). In the 
canonical pathway, the RNA polymerase II processes hairpin-shaped gene transcripts, 
which are further cleaved into ~70 nt pre-miRNA by the RNase III family member enzyme 
Drosha. Some miRNA orginate from short introns and are processed into pre-miRNA in a 
spliceosome complex independently of Drosha (non-canonical pathway). The pre-miRNA 
are exported into the cytoplasm, where Dicer, another RNase III family member enzyme, 
cleaves the pre-miRNA products into a double-stranded (ds) miRNA molecule. In the miRNA 
biogenesis, Drosha and Dicer operate in concert with accessory proteins and enzymes like 
ds-RNA-binding-proteins (RBP) or transactivation-responsive RBP. Typically, the ds-miRNA 
possesses one guide strand and one passenger strand. The guide strand is preferentially 
loaded into a miRNA-silencing complex (miRISC), where the mature miRNA base pairs with 
its respective mRNA. In opposition to former assumptions, where the passenger strand was 
determined to degradation, it is now accepted, that this strand can also be incorporated into 
the miRISC. Besides a number of cofactors, Argonaute (AGO) proteins and glycine-
tryptophan protein of 182 kDa (GW182) represent the core components of the miRISC. In 
mammals, AGO2 proteins interact with the miRNA and promote mRNA cleavage and 
subsequently degradation, while GW182 proteins contain functional regions which repress 
the translation or facilitate 3‘ deadenylation of the mRNA (Krol et al. 2010). 
Since the spatiotemporal expression of miRNA is indispensable for adequate protein 
expression from very early developmental processes on, their expression, processing and 
function have to be strictly controlled. Similar to protein-coding genes, miRNA encoding 
genes can be activated by transcription factors, enhancers and transcriptional co-factors. 
miRNA often act in autoregulatory feedback circuits by targeting factors involved in their 
biogenesis or their function. Additionally, several factors regulate miRNA processing through 
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protein-protein interaction as described for the proteins Drosha and Dicer, whose function is 
dependent on sufficient RBP levels. Modifications of the 3’ end through adenylation, 
uridylation or methylation can further stabilize or destabilize the miRNA. Moreover, miRNA 
function can be altered by the respective AGO protein or the AGO protein level as shown for 
AGO2, where low levels are limiting the miRISC loading.  
 
1.3.2 miRNA function in the immune system 
The role of miRNA in immune dysfunctions such as allergic diseases became more evident 
during the last years. Several miRNA were discovered to be involved in the regulation of 
inflammation, in immune receptor expression and signal transduction processes. Among 
them, miRNA-146a-5p (abbreviated to miRNA-146a) and miRNA-155-5p (abbreviated to 
miRNA-155) may be the most intensively studied miRNA in pro- and in anti-inflammatory 
immune responses (reviewed in (Rebane and Akdis 2014)). Both miRNA have been 
described to be involved in different TLR signaling processes. 
In 1997, Tam et al. became aware that the B cell integration cluster (BIC) gene is activated 
by proviral integration of the avian leucosis virus in B cell lymphomas. Interestingly, the BIC 
gene was found to lack an open reading frame, but formed an imperfect RNA duplex 
probably functioning as a non-coding RNA (Tam 2001, Tam et al. 1997). Further studies 
revealed that miRNA-155 is processed by the BIC gene and that both, BIC as well as 
miRNA-155, accumulate in human lymphoma cells (Eis et al. 2005). Due to the fact that the 
BIC gene harbors the primary miR-155 (pri-miR-155) in a phylogenetically conserved region 
of the BIC gene, the gene’s name was designated MIR155 host gene (MIR155HG). In the 
following years, miRNA-155 was found to be involved in many physiological and 
pathological processes like hematopoiesis, immunity, inflammation or cancer (reviewed in 
(Elton et al. 2013)). For example, miRNA-155 is indispensable for normal immune function 
as shown by miRNA-155 deficient mice, which produce less IgM, less antigen-specific 
antibodies and show an impaired production of IL-2 and IFN-γ cytokines by splenocytes 
upon activation (Rodriguez et al. 2007). During monocyte differentiation into DC (mDC), 
miRNA-155 is upregulated and is involved in the regulation of DC development as well as in 
apoptotic processes (Lu et al. 2011). DC lacking miRNA-155 are incapable of presenting 
antigens to naïve T cells (Rodriguez, Vigorito et al. 2007). Compared to DC, the expression 
of miRNA-155 is low in LC (Jurkin et al. 2010). In different myeloid cells, miRNA-155 is 
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highly induced upon activation through different TLR ligands such as Pam3Cys-Ser-(Lys)4 
(P3C) for TLR2, polyriboinosinic:polyribocytidylic acid (poly(I:C)) for TLR3, 
lipopolysaccharides (LPS) for TLR4 and hypomethylated DNA for TLR9 (O'Connell et al. 
2007).  
For miRNA-155, a huge number of validated and predicted target mRNA 
(http://www.mirbase.org/) is indicative for the multi-functionality of this special miRNA that is 
involved in many biological and pathological processes like haematopoiesis, cancer and 
inflammation (reviewed in (Faraoni et al. 2009)). It directly targets many key regulators such 
as PU.1 (Martinez-Nunez et al. 2009) or C/EBPß (Costinean et al. 2009). In immunity, 
miRNA-155 exhibits pro- and anti-inflammatory functions. The pro-inflammatory ones are 
based on targeting the suppressor of cytokine signaling 1 (SOCS-1), which attenuates the 
production of inflammatory cytokine production (Wang et al. 2010), or the inositol 
polyphosphate-5-phosphatase D (SHIP-1), a negative regulator of myeloid cell proliferation 
(Cremer et al. 2009, O'Connell et al. 2009). Moreover, miRNA-155 overexpression in 
activated CD4+ T cells is expected to promote TH1 proliferation by suppressing IFN-γ 
(Banerjee et al. 2010). Additionally, miRNA-155 targets CTLA-4, an anti-proliferative 
molecule in T cell responses (Sonkoly et al. 2010). On the other side, the termination of 
inflammation is supported by targeting TLR/IL-1 signaling downstream factors like the 
myeloid differentiation primary response gene 88 (MYD88) or the TGF-ß activated kinase 
1/MAP3K7 binding protein 2 (TAB2) (Ceppi et al. 2009).  
By targeting mRNA of genes mentioned above, miRNA-155 is suggested to influence 
cytokine release, T cell proliferation and inflammation in allergic disease such as AD, where 
miRNA-155 is elevated in lesional skin compared to skin of healthy donors (Sonkoly, Janson 
et al. 2010). Major contributors to the increased miRNA-155 levels in inflamed skin are T 
cells and DC. 
While miRNA-155 has pro- and anti-inflammatory properties, miRNA-146a has been 
described to act predominantly as a negative regulator of innate immune responses 
(reviewed in (Saba et al. 2014)). In human LC, miRNA-146a shows a high basal expression 
level which is maintained by a TGF-ß1-dependent PU.1 expression, a positive regulator for 
this miRNA (Jurkin, Schichl et al. 2010). Upon TLR2 engagement, miRNA-146a expression 
was shown to be further elevated in the monocytic cell line THP-1 but not in LC (Taganov et 
al. 2006). miRNA-146a is not only regulated through PU.1, but also through NF-κB which in 
turn is increased upon TLR activation. In an auto-regulatory loop, miRNA-146a controls its 
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own expression by reducing NF-κB expression through targeting TLR signaling upstream 
molecules such as TNF receptor-associated factor 6 (TRAF6) or IL-1 receptor-associated 
kinase 1 (IRAK1) (Taganov, Boldin et al. 2006). In monocytes, miRNA-146a plays a pivotal 
role in endotoxin tolerance against LPS-induced TLR4 activation. Cells subsequently primed 
with low doses of LPS show a hyporesponsiveness to LPS as a result of miRNA-146a-
dependent TRAF6 and IRAK1 reduction (Nahid et al. 2009). Moreover, challenging 
monocytes with LPS induces cross-tolerance to other TLR ligands like peptidoglycan (PGN), 
P3C or even inactivated bacteria (Nahid et al. 2011). In AD, miRNA-146a levels are 
upregulated in cultured primary keratinocytes and lesional as well as non-lesional skin 
samples. Here, miRNA-146a inhibits the expression of several pro-inflammatory factors 
such as IL-6, IL-8 or the chemokine C-C motif ligand 8 (CCL8) via IRAK1 and caspase 
recruitment domain-containing protein 10 (CARD10) -dependent NF-κB reduction. 
Moreover, miRNA-146a directly targets the inducible chemokine C-C motif ligand 5 (CCL5, 
also known as RANTES), a chemokine for the recruitment of T cells, macrophages and 
eosinophils to the site of inflammation (Rebane et al. 2014). Thus, in AD miRNA-146a is an 
important player in controlling NF-κB- and CCL5-dependent skin inflammation. 
 
1.4 Objectives of this work 
Allergic diseases show an increasing prevalence mostly in industrialized countries. Among 
them, AD is considered to be the most common inflammatory skin disease that appears in 
10 to 20 % during the childhood and persists throughout adulthood in 1 to 3 %. People 
suffering from AD are often restricted in their life quality. Although considerable research 
shed light on the genetics, the epidemiology and the pathophysiology of the disease, there 
is further need to understand the complexity of AD and to evolve new therapeutic strategies. 
Previous work has demonstrated that skin DC expressing FcεRI play a pivotal role in the 
course and the severity of TLR-induced skin inflammation (Herrmann, Koch et al. 2013).  
This study was designed to gain further insights into the molecular regulation of FcεRI on 
human DC. For this purpose, a model of human CD34+-derived LC expressing FcεRI was 
used:  
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 first to analyze the regulation of FcεRI upon stimulation of the cells with different TLR 
ligands as well as with heat-killed bacteria suspensions to mimic AD skin conditions;  
 
 secondly to elucidate how FcεRI is regulated at the transcriptional level and  
 
 thirdly to find out how the factors promoting FcεRI expression are regulated in steady-
state cells compared to inflammatory conditions.  
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2 Material 
2.1 Chemicals 
Table 1 Chemicals 
Chemical  Manufacturer 
2-Mercaptoethanol Sigma-Aldrich Chemie GmbH; Taufkirchen, 
Germany 
7-AAD Sigma-Aldrich Chemie GmbH; Taufkirchen, 
Germany 
Agarose Sigma-Aldrich Chemie GmbH; Taufkirchen, 
Germany 
Antibiotic-antimycotic (100x)  Gibco®; Karlsruhe, Germany 
BSA  Sigma-Aldrich Chemie GmbH; Taufkirchen, 
Germany 
Chloroform AppliChem GmbH; Darmstadt, Germany 
Dextran Sigma-Aldrich Chemie GmbH; Taufkirchen, 
Germany 
DMSO Sigma-Aldrich Chemie GmbH; Taufkirchen, 
Germany 
dNTP Life Technologies GmbH; Darmstadt, Germany 
DTT Carl Roth GmbH & Co. KG; Essen, Germany 
EDTA Merck KGaA, Darmstadt, Germany 
Ethanol AppliChem GmbH; Darmstadt, Germany 
Ethidium bromid solution Sigma-Aldrich Chemie GmbH; Taufkirchen, 
Germany 
Fetal calf serum (Gibco®) Life Technologies GmbH; Darmstadt, Germany 
FLT3L (rhFlt3/Flk2 ligand)  R&D Systems Inc.; Minneapolis, USA 
Gel Loading Dye Blue, (6x) New England Biolabs; Frankfurt am Main, 
Germany 
Glycin AppliChem GmbH; Darmstadt, Germany 
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Table 1 Chemicals (continued) 
Chemical  Manufacturer 
GM-CSF Bayer AG; Leverkusen, Germany 
Human IgG, Myeloma Calbiochem® by Merck Chemicals GmbH; Darmstadt, 
Germany 
Isopropanol AppliChem GmbH; Darmstadt, Germany 
LB Broth (Lennox) Carl Roth GmbH + Co. KG; Karlsruhe, Germany 
Lipofectamine® RNAiMAX Transfection 
Reagent (Ambion™) 
Life Technologies GmbH; Darmstadt, Germany 
Lymphoprep™ Progen Biotechnik GmbH; Heidelberg, Germany 
Normal mouse serum Jackson ImmunoResearch Labaratories, Inc; West 
Grove, USA 
Opti-MEM® I Reduced Serum Medium 
(Gibco™) 
Life Technologies GmbH; Darmstadt, Germany 
Pam3Cys-Ser-(Lys)4 trihydrochloride EMC microcollections GmbH; Tübingen, Germany 
Quick-Load® 2-Log DNA Ladder (0.1-10.0 
kb) 
New England Biolabs; Frankfurt am Main, Germany 
Quick-Load® 50 bp DNA Ladder New England Biolabs; Frankfurt am Main, Germany 
RPMI Medium 1640 (1x) + GlutaMAX™ -l 
(Gibco®) 
Life Technologies GmbH; Darmstadt, Germany 
SCF R&D Systems Inc.; Minneapolis, USA 
SYBR® Green Supermix with ROX™ Bio-Rad Laboratories Inc.; Hercules, USA 
TGF-ß R&D Systems Inc.; Minneapolis, USA 
TNF-α R&D Systems Inc.; Minneapolis, USA 
TRIzol® Life Technologies GmbH; Darmstadt, Germany 
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2.2 Buffers 
Table 2 Composition of buffers 
Buffers (1x) Composition 
FACS buffer 137 mM NaCl; 75 mM Na2HPO4; 32.5 mM NaH2PO4; 10 % (v/v) FCS; 
155 mM NaN3 
MACS buffer 137 mM NaCl; 2.7 mM KCl; 8.5 mM Na2HPO4; 1.47 mM KH2PO4; 
0.5 % (w/v) BSA; 1 % (v/v) 0.5 M EDTA 
PBS 137 mM NaCl; 2.7 mM KCl; 8.5 mM Na2HPO4; 1.47 mM KH2PO4 
TAE buffer 40 mM Tris/acetic acid, pH 7.8; 10 mM NaAc; 1 mM EDTA, pH 8.0 
 
 
 
2.3 Cell culture media 
Table 3 Composition of cell culture media 
Name Composition 
CD34+ medium RPMI Medium 1640 (1x) + GlutaMAX™ -l; 10 % (v/v) FCS; 1 % (v/v) 
AB/AM; 50 µM 2-mercaptoethanol 
CD34+ transfection medium RPMI Medium 1640 (1x) + GlutaMAX™ -l; 10 % (v/v) FCS;  
50 µM 2-mercaptoethanol 
freezing medium FCS; 10 % DMSO 
LB medium Tryptone 10 g/L; Yeast extract 5 g/L; NaCl 5 g/L; ad 1 L distilled 
water 
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2.4 Kits 
Table 4 Kits 
Kit Manufacturer 
BD Cytofix/Cytoperm™ Beckton Dickinson GmbH; Heidelberg, Germany 
CD1a MicroBeads, human Miltenyi Biotec GmbH; Bergisch Gladbach, Germany 
DNA-free™ DNA Removal Kit (Ambion®) Life Technologies GmbH; Darmstadt, Germany 
Indirect CD34 MicroBead Kit, human Miltenyi Biotec GmbH; Bergisch Gladbach, Germany 
Invisorb® Spin Plasmid Mini Two STRATEC Biomedical AG; Birkenfeld, Germany 
TaqMan® MicroRNA Assays 
- hsa-miR-155-5p (ID 002623) 
- hsa-miR-146a-5p (ID 000468) 
- RNU48 (ID 001006) 
Life Technologies GmbH; Darmstadt, Germany 
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2.5 Antibodies 
Table 5 Antibodies used for flow cytometry analysis  
Antibody / 
conjugation 
Immunogen / 
specificity 
Clone Species Isotype Manufacturer 
CD14-APC human CD14 TÜK4 mouse IgG2a Miltenyi Biotec GmbH; 
Bergisch Gladbach, 
Germany 
CD34-PE human CD34 581 mouse IgG1, κ Beckton Dickinson 
GmbH; Heidelberg, 
Germany 
CD83 human CD83  HB15a mouse IgG2b Beckman Coulter Inc.; 
Krefeld, Germany 
FcεRIα human FcεRIα AER-37 
(CRA1) 
mouse IgG2b, κ eBioscience; San Diego, 
USA 
Goat anti-
mouse IgG, 
Fcγ -FITC 
mouse IgG Fcγ polyclonal goat IgG Jackson 
ImmunoResearch 
Europe Ltd.; Suffolk, UK 
Langerin 
(CD207) 
CD34-derived 
dendritic cells 
DCGM4 mouse IgG1 Beckman Coulter Inc.; 
Krefeld, Germany 
PU.1 human PU.1 A-7 mouse IgG1 Santa Cruz 
Biotechnology, Inc.; 
Heidelberg, Germany 
CD1a-RD1 
(T6-RD1) 
human CD1a SFCI19Thy1
A8 
mouse IgG1 Beckman Coulter Inc.; 
Krefeld, Germany 
TLR2 human TLR2 1030A5.138 mouse IgG1 Immgenex; San Diego, 
USA 
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Table 6 Isotype control antibodies used for flow cytometry analysis 
Antibody / 
conjugation 
Clone Isotype control for Manufacturer 
IgG1, κ MOPC-21 anti-PU.1 Sigma-Aldrich Chemie GmbH; 
Taufkirchen, Germany 
IgG2b, κ MOPC-141 anti-FcεRI, anti-CD83, 
anti-Langerin 
Sigma-Aldrich Chemie GmbH; 
Taufkirchen, Germany 
IgG1-PE X40 anti-CD34-PE Beckton Dickinson GmbH; 
Heidelberg, Germany 
IgG1-RD1 2T8-2F5 anti-CD1a-RD1 Beckman Coulter Inc.; Krefeld, 
Germany 
IgG2a-APC 
 
S43.10 
 
anti-CD14-APC 
 
Miltenyi Biotec GmbH; Bergisch 
Gladbach, Germany 
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2.6 Oligonucleotides 
Table 7 Amplicons, Oligonucleotides and cDNA clone used for qPCR. Matching sequences for 
oligonucleotides in amplicons are underlined. Amplicons and oligonucleotides were manufactured by Life 
Technologies GmbH; Darmstadt, Germany. 
Gene Forward sequence (5’ → 3’)  Reverse sequence (5’ → 3’)  
Amplicon Amplicon sequence (5’ → 3’) 
hACTB AGCGCGGCTACAGCTTCA TCCTTAATGTCACGCACGATTT 
AmphACTB TCCTCACCGAGCGCGGCTACAGCTTCACCACCACGGCCGAGCGGGAAAT
CGTGCGTGACATTAAGGAGAAGCTGT 
FCER1A GGCAGCTGGACTATGAGTCTGA CTTCTCACGCGGAGCTTTTATT 
pDNR -LIB 
FCER1A 
For further information and FCER1A sequence in this clone see: 
http://www.ncbi.nlm.nih.gov/nuccore/BC005912 and Table 8.  
FCER1G GATGCCATCCTGTTTCTGTATGG CACTTGGATCTTCAGTCGACAGTAG 
AmpFCER1G CTATATCCTGGATGCCATCCTGTTTCTGTATGGAATTGTCCTCACCCTCCT
CTACTGTCGACTGAAGATCCAAGTGCGAAAGGCAG 
ELF1 TGCCCCAGTCACCCATGT ACCCGGTGAGTCTGCATATT 
AmpELF1_IsoA TGTTGCCCCAGTCACCCATGTGTCCGTCACATTAGATGGGATTCCTGAAGT
GATGGAAACACAGCAGGTGCAAGAAAAATATGCAGACTCACCGGGAGCC 
PU.1 GGAGAGCCATAGCGACCATT GGAGCTCCGTGAAGTTGTTC 
AmpPU.1 ATGGGGAGAGCCATAGCGACCATTACTGGGACTTCCACCCCCACCACGTG
CACAGCGAGTTCGAGAGCTTCGCCGAGAACAACTTCACGGAGCTCCAGAG 
YY1 GTTCAGGGATAACTCGGCCA TTCTGCACAGACGTGGACTC 
AmpYY1 GCACAAAGATGTTCAGGGATAACTCGGCCATGAGAAAACATCTGCACACC
CACGGTCCCAGAGTCCACGTCTGTGCAGAATGTGGCAAAG 
HMGB1 GATCCTAAGAAGCCGAGAGGC CTTATGCTCCTCCCGACAAGT 
AmpHMGB1 GGGCAAAGGAGATCCTAAGAAGCCGAGAGGCAAAATGTCATCATATGCAT
TTTTTGTGCAAACTTGTCGGGAGGAGCATAAGAAGAAGCACC 
HMGB2 CCCGGACTCTTCCGTCAATT TCTTCCATCTCTCCGAACACTTC 
AmpHMGB2 AGAAGAAACACCCGGACTCTTCCGTCAATTTCGCGGAATTCTCCAAGAAGT
GTTCGGAGAGATGGAAGACCATGTCTGC 
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Table 7 Amplicons, Oligonucleotides and cDNA clone used for qPCR (continued I) 
Gene Forward sequence (5’ → 3’)  Reverse sequence (5’ → 3’)  
Amplicon Amplicon sequence (5’ → 3’) 
SP1 GGACTACCTGGAGTGATGCCTAA CCCATCAACGGTCTGGAACT 
AmpSP1 AGTTCTGACAGGACTACCTGGAGTGATGCCTAATATTCAGTATCAAGTAATC
CCACAGTTCCAGACCGTTGATGGGCAACAGCTGC 
GATA1 TGTGAACTGCGGAGCAACAG GCAGGCGTTGCATAGGTAGTG 
AmpGATA1 CCAGGGAGTGTGTGAACTGCGGAGCAACAGCCACTCCACTGTGGCGGAGG
GACAGGACAGGCCACTACCTATGCAACGCCTGCGGCCTCTATC 
GATA2 AAGGACGGCGTCAAGTACCA GGGACTGCCACTTTCCATCTT 
AmpGATA2 AGGAGAGGACAAGGACGGCGTCAAGTACCAGGTGTCACTGACGGAGAGCA
TGAAGATGGAAAGTGGCAGTCCCCTGCGCCCAG 
TLR1 TGTGCTGCCAATTGCTCATT TTTTCCCCATAAGTCTCTCCTAAGAC 
AmpTLR1 CACTTAGAAAAATCTAGTGTGCTGCCAATTGCTCATTTGAATATCAGCAAGG
TCTTGCTGGTCTTAGGAGAGACTTATGGGGAAAAAGAAGACCCT 
TLR2 CCAAGGAAGAATCCTCCAATCA GCTGCCCTTGCAGATACCA 
AmpTLR2 ATCAGCCTCTCCAAGGAAGAATCCTCCAATCAGGCTTCTCTGTCTTGTGACC
GCAATGGTATCTGCAAGGGCAGCTCAGGATCTT 
TLR6 GGGACTCAGCATGGTAGAAGGTA CTCCTGTTACTCTGCAAGCTTTCA 
AmpTLR6 TGCAGACAAGTGTGAGGGACTCAGCATGGTAGAAGGTAGCCTGGCATCCCA
CTCCAAGACTGAAAGCTTGCAGAGTAACAGGAGCACACAGGTTCAGTG 
MYD88 TCACTGTCTGCGACTACACCAA GGCAAGGCGAGTCCAGAAC 
AmpMYD88 CCTGAGGTTCATCACTGTCTGCGACTACACCAACCCCTGCACCAAATCTTGG
TTCTGGACTCGCCTTGCCAAGGCCTTGT 
CCR6 CCATTCTGGGCAGTGAGTCA GCACGTGGCATTGCTGAA 
AmpCCR6 TCTTACTCTCCCATTCTGGGCAGTGAGTCATGCCACCGGTGCGTGGGTTTT
CAGCAATGCCACGTGCAAGTTGCTAA 
CCR7 GCTGCGTCAACCCTTTCTTG AAGAGATCGTTGCGGAACTTG 
AmpCCR7 TGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAG
TTCCGCAACGATCTCTTCAAGCTCTTC 
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Table 7  Amplicons, Oligonucleotides and cDNA clone used for qPCR (continued II) 
Gene Forward sequence (5’ → 3’)  Reverse sequence (5’ → 3’)  
Amplicon Amplicon sequence (5’ → 3’) 
CD83 GCCTCGAAAACCATCACATGA GGTGGCCATGGAGAAGCA 
AmpCD83 CTGTGGGCAGGCCTCGAAAACCATCACATGACCACATAGCATGAGGCCA
CTGCTGCTTCTCCATGGCCACCTTTTCAGCGA 
hGABPA ACGCCTTGGGATACCCTATGA ACCACCCAATGCAGGACTTG 
AmpGABPA AAGAACAAGAACGCCTTGGGATACCCTATGATCCCATACAGTGGTCCACA
GACCAAGTCCTGCATTGGGTGGTTTGGGTAAT 
hCEBPA CGAGCACGAGACGTCCATC AGGAACTCGTCGTTGAAGGC 
AmpCEBPA CCGCTGGGCGGCATCTGCGAGCACGAGACGTCCATCGACATCAGCGCCT
ACATCGACCCGGCCGCCTTCAACGACGAGTTCCTGGCCGACCTG 
 
 
2.7 cDNA clone 
Table 8 Specifications of the cDNA clone used for human FCER1A cDNA. For FCER1A sequence in this 
clone see: http://www.ncbi.nlm.nih.gov/nuccore/BC005912. 
Clone ID  Gene bank 
accession 
Gene Species Vector Selection 
4294467 BC005912 FCER1A Homo sapiens pDNR-LIB chloramphenicol 
 
 
2.8 Restriction enzymes 
Table 9 Restriction enzymes 
Name  Recognition site Manufacturer 
EcoRI 5’…GʹAATTC…3’ 
3’…CTTAAʹG…5’ 
New England Biolabs; Frankfurt am 
Main, Germany 
XhoI 5’…CʹTCGAG…3’ 
3’…GAGCZʹC…5’ 
New England Biolabs; Frankfurt am 
Main, Germany 
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2.9 Micro-RNA molecules 
Table 10  Micro-RNA (miRNA) molecules used for transfection experiments. miRNA precursor and inhibitor 
molecules were purchased from Life Technologies GmbH; Darmstadt, Germany. 
miRNA Name miRBase Accession # Species 
Ambion® Pre-miR™ Precursor  
for hsa-miR-155-5p 
MIMAT0000646 Homo sapiens 
Ambion® Pre-miR™ Precursor  
for hsa-miR-146a-5p 
MIMAT0000449 Homo sapiens 
Ambion® Pre-miR™ miRNA Precursor 
Molecules - Negative Control # 1 
synthetically derived miRNA - 
BLOCK-iT™ Alexa Fluor® Red Fluorescent 
Control (Ambion™) 
synthetically derived miRNA - 
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2.10 Devices and consumables 
Table 11  Devices and consumables 
Name  Manufacturer 
Nunc™ Biobanking and Cell Culture Cryogenic 
Tubes, 1.8 mL 
Thermo Fisher Scientific Inc.; Waltham, USA 
Mr. Frosty™ Freezing Container Thermo Fisher Scientific Inc.; Waltham, USA 
Safe-Lock Tubes, 0.5 mL / 1.5 mL, PCR clean Eppendorf AG; Hamburg, Germany 
15 mL / 50 mL CELLSTAR® Polypropylene Tube Greiner Bio-One GmbH; Frickenhausen, 
Germany 
Pipettors Gilson Inc.; Middleton, USA 
Eppendorf AG; Hamburg, Germany 
CELLSTAR® Serological Pipet, 10 mL, sterile Greiner Bio-One GmbH; Frickenhausen, 
Germany 
Costar® Stripette® Serological Pipets, 
Polystyrene, 5 mL / 10 mL, sterile 
Corning GmbH HQ; Wiesbaden, Germany 
Costar® 24 Well Clear TC-Treated Multiple Well 
Plates, Individually Wrapped, sterile 
Corning GmbH HQ; Wiesbaden, Germany 
Polypropylene Tubes - Two-Position Vent 
Stopper Tube, 5 mL 
Greiner Bio-One GmbH; Frickenhausen, 
Germany 
Falcon® 14 mL Round Bottom High Clarity PP 
Test Tube, Graduated, with Snap Cap, Sterile, 
Corning GmbH HQ; Wiesbaden, Germany 
Whatman® Puradisc 30 syringe filters, pore size 
0.2 μm 
GE Healthcare; Chalfont St. Giles, Great Britain 
Pre-Separation Filters (30 µm) Miltenyi Biotec GmbH; Bergisch Gladbach, 
Germany 
MicroAmp® Fast Optical 96-Well Reaction Plate 
with Barcode, 0.1 mL 
Applied Biosystems® by Life Technologies 
GmbH; Darmstadt, Germany 
Opti-Seal Optical Disposable Adhesive BIOplastics; Landgraaf, Netherlands 
 
 
Mater ial   29 
2.11 Instruments 
Table 12  Instruments 
Name  Manufacturer 
Autoclave Varioclav 500 H+P Labortechnik AG; Oberschleißheim, Germany 
AutoMACS Pro® Separator Miltenyi Biotec GmbH; Bergisch Gladbach, Germany 
Centrifuge 5417R Eppendorf AG; Hamburg, Germany 
Centrifuge Allegra® X-15R  Beckman Coulter Inc.; Brea, USA 
Centrifuge Rotixa 120 RS  Hettich GmbH & Co.KG; Tuttlingen, Germany 
Flow Cytometer FACSCanto™  Beckton Dickinson GmbH; Heidelberg, Germany 
Horizontal Electrophoresis System Wide Mini-
Sub Cell GT Cell 
Bio-Rad Laboratories GmbH; München; Germany 
ImageQuant™ LAS 4000 GE Healthcare; Chalfont St. Giles, UK 
Incubator Heracell™ 150 and 150i Thermo Fisher Scientific Inc.; Waltham, USA 
Incubator Heraeus Function Line Hereaus Material Technology GmbH & Co. KG; 
Hanau, Germany  
Incubator Shaker Innova 4000 New Brunswick Scientific; Enfield, USA 
Laboclav 135 MSLV  SHP Steriltechnik AG; Detzel Schloss, Germany 
Mastercycler nexus gradient Eppendorf AG; Hamburg, Germany 
Microscope Leica DM IRB Leica Camera AG; Bensheim, Germany 
Microscope Nikon Eclipse TS100 Nikon GmbH; Düsseldorf, Germany 
Milli-Q® Reference Water Purification System Merck KGaA, Darmstadt, Germany 
 
Neubauer improved hemocytometer Brand GmbH & Co. KG; Wertheim, Germany 
Power supply PowerPac™ 3000  Bio-Rad Laboratories GmbH; München; Germany 
qPCR machine StepOne™ plus Applied Biosystems® by Life Technologies GmbH; 
Darmstadt, Germany 
Synergy™ HT Multi-Mode Microplate Reader BioTek Germany; Bad Friedrichshall, Germany 
Thermomixer 5436 Eppendorf AG; Hamburg, Germany 
30 Mater ial  
2.12 Software 
Table 13  Software 
Software Manufacturer 
FlowJo 7.6.1 FlowJo, LLC Data Analysis Software; Ashland, 
USA 
BD FACS Diva Software Beckton Dickinson GmbH; Heidelberg, Germany 
StepOne™ Software v2.2.2 Applied Biosystems® by Life Technologies GmbH; 
Darmstadt, Germany 
Microsoft Office 2010 Microsoft Corporation; Redmond, USA 
IBM SPSS Statistics 22 IBM Deutschland GmbH; Ehningen, Germany 
Primer Express 3.0.1 Applied Biosystems® by Life Technologies GmbH; 
Darmstadt, Germany 
NCBI/ Primer-BLAST www.ncbi.nlm.nih.gov/tools/primer-blast/ 
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3 Methods 
3.1 Cell biological methods 
3.1.1 Isolation of peripheral blood mononuclear cells (PBMC) from human 
cord blood 
Human cord blood was provided by the Johanniter-Hospital Bonn and the St. Marien-
Hospital Bonn, Germany, respectively. The use of human cord blood was approved by the 
local ethics committee of the University of Bonn in accordance with the declaration of the 
Helsinki principles. Samples were collected in 50 mL tubes prepared with 250 µL Heparin 
and stored at 4 °C until processing. PBMC were isolated using Lymphoprep™ density 
gradient medium. Cord blood was mixed 1:2 with PBS, layered on Lymhpoprep™ and 
centrifuged (800 x g, 20 °C, 28 min, break off). The PBMC containing interphase was 
collected and subject to magnetic-activated cell sorting (MACS®) for enrichment of CD34+ 
hematopoietic stem cells (see 3.1.2).  
 
3.1.2 Magnetic-activated cell sorting (MACS®)  
The MACS® Technology (Miltenyi Biotec GmbH; Bergisch Gladbach, Germany) is used to 
enrich different cell types of a single-cell solution by magnetic labeling of the cell surface 
molecules. Cells are separated by a magnetic field within an AutoMACS Pro® Separator 
(Miltenyi Biotec GmbH; Bergisch Gladbach, Germany). 
PMBC (see 3.1.1) were washed first with 15 mL PBS (400 x g, 20 °C, 10 min) and then with 
25 mL 4 °C MACS buffer (230 x g, 4 °C, 10 min). Cells were resuspended in 1 mL 4 °C 
MACS buffer and were labeled magnetically according to the manufacturers’ instructions of 
the CD34 MicroBead Kit (Miltenyi Biotec GmbH; Bergisch Gladbach, Germany). CD34+ 
hematopoietic stem cells were prepared for cryopreservation in liquid nitrogen (see 3.1.3) or 
were differentiated into CD34+ hematopoietic stem cell derived LC (CD34LC) (see 3.1.4).  
CD1a+ cells were enriched from CD34LC following the manufacturer’s protocol of the CD1a 
MicroBeads kit from Miltenyi Biotec GmbH; Bergisch Gladbach, Germany. CD1a+ enriched 
cells were resuspended in 1 mL TRIzol® reagent for RNA isolation (see 3.2.2).  
The purity of enriched cell fractions was confirmed by flow cytometry analysis (see 3.1.8). 
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3.1.3 Cryopreservation of CD34+ hematopoietic stem cells 
Freshly isolated CD34+ stem cells can be stored in liquid nitrogen for extended times in 
order to use them for further experiments at later time points.  
 
I Freezing of CD34+ hematopoietic stem cells 
CD34+ hematopoietic stem cells were counted (Neubauer improved hemocytometer), 
centrifuged (300 x g, 4 °C, 5 min), resuspended in 1 mL freezing medium and transferred 
into a 1.8 mL cryogenic tube. For slow freezing conditions, cells were placed into an 
isopropanol freezing container (cooling speed 1 °C/min) and were stored at -70 °C for one 
day before they were transferred into liquid nitrogen for long term storage.  
 
II Thawing of CD34+ hematopoietic stem cells 
CD34+ hematopoietic stem cells were thawed in a 37 °C water bath directly after removing 
them from liquid nitrogen. Cells were washed in 37 °C RPMI Medium 1640 (1x) + 
GlutaMAX™ -l (Gibco®) (300 x g, 20 °C, 5 min) and adjusted to 0.6 to 0.8 x 106 cells/mL in 
CD34+ medium. CD34+ hematopoietic stem cells were processed to in vitro generated 
CD34LC (see 3.1.4). 
 
3.1.4 In vitro generation of CD34+ hematopoietic stem cell derived LC 
Freshly isolated or thawed CD34+ hematopoietic stem cells were adjusted to 0.6 to 
0.8 x 106 cells/mL CD34+ medium and cultured in a 24-well plate at 37 °C and 5 % CO2 for 8 
to 12 days. Culture conditions are summarized in Table 13. Cells were harvested between 
d8 and d12. The LC phenotype was analyzed by flow cytometry (see 3.1.9). CD34LC were 
used for stimulation or transfection experiments (see 3.1.5 and 3.1.6). 
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Table 14  Culture conditions for CD34+ hematopoietic stem cell derived LC. Final concentrations are listed. 
Reagent d0 d2 d4 d6 d8 
GM-CSF 300 U/mL  200 U/mL  300 U/mL 
mIgE 10³ ng/mL 10³ ng/mL 10³ ng/mL 10³ ng/mL 10³ ng/mL 
FLT3L 10 ng/mL     
SCF 10 ng/mL     
TGF-ß 0.5 ng/mL  0.5 ng/mL  0.5 ng/mL 
TNF-α 20 U/mL     
Culture volume / well 0.50 mL 0.50 mL 0.75 mL 0.75 mL 1.00 mL 
 
 
3.1.5 TLR-mediated stimulation of CD34LC 
CD34LC were adjusted to 106 cells/mL in freshly prepared CD34+ medium including 
300 U/mL GM-CSF and were distributed in 24-well plates with 1 mL per well. For time 
course experiments a maximum of 2 mL cell suspension was used per 14 mL stimulation 
tube. Cells were left untreated or treated with specific stimulants (see Table 14) and were 
incubated at 37 °C and 5 % CO2 for 24 h or for the indicated time periods. Stimulation effects 
were analyzed by flow cytometry of all CD34LC (see 3.1.7). CD1a+ enriched cell fractions 
(see 3.1.2) were examined by quantitative polymerase chain reaction (qPCR) (see 3.2.8) and 
TaqMan® MicroRNA Assays (see 3.2.9). 
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Table 15  Ligands for TLR-mediated stimulation of CD34LC 
Stimulant / 
treatment 
Derived from  Final 
concentration 
Used as 
ligand for 
Achieved from 
FSL-1 Synthetic diacylated 
lipoprotein derived from 
Mycoplasma salivarium  
16.6 x 10-3 
µg/mL 
TLR2 / 
TLR6 
EMC microcollections 
GmbH; Tübingen, 
Germany 
LTA Staphylococcus aureus 
(S.a.) 
1.0 µg/mL TLR2 / 
TLR6 
InvivoGen; San Diego, 
USA 
LPS E. coli 0111:B4 0.1 µg/mL TLR4 InvivoGen; San Diego, 
USA 
S.p. Heat-killed 
Streptococcus 
pyogenes (S.p.) 
serotype M49 
6.5 x 109 
cells/mL 
TLR2 kind gift from  
R. Lütticken (University 
of Aachen, Germany) 
S.a. Heat-killed, formalin-
fixed S.a. Cowan 1 
10 µL 
suspension/mL 
TLR2 Merck KGaA; 
Darmstadt, Germany 
P3C Synthetic triacylated 
lipopeptide 
1.0 µg/mL TLR1 / 
TLR2 
EMC microcollections 
GmbH; Tuebingen, 
Germany 
“untreated” - equal volume of 
medium 
-  
 
 
3.1.6 Transfection of CD34LC with miRNA precursor molecules 
miRNA precursor molecules are synthetically produced double-stranded small RNA 
molecules. They mimic endogenous pre-miRNA molecules and are processed to functionally 
mature miRNAs in the cell. Transfection of CD34LC with miRNA precursor molecules was 
achieved by using Lipofectamine® RNAiMAX Reagent (Life Technologies GmbH; Darmstadt, 
Germany). In aqueous environment, Lipofectamine® RNAiMAX forms cationic liposomes 
that incorporate RNA molecules. These liposomes can fuse with the negatively charged cell 
membrane and the RNA is released into the cytoplasm. 
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For transfection experiments, CD34 medium without AB/AM was used. This avoided cell 
irritations due to a possible transferring of AB/AM into the cells via Lipofectamine vesicles. 
miRNA were adjusted to a working concentration of 10 µM. Target miRNA pre-
miRNA-155-5p, pre-miRNA-146a-5p and negative control miRNA Pre-miR™ miRNA 
Precursor Molecules - Negative Control # 1 (Ambion®, Life Technologies GmbH; Darmstadt, 
Germany) were resuspended in nuclease-free water. Control miRNA BLOCK-iT™ Alexa 
Fluor® Red Fluorescent Control (Ambion™, Life Technologies GmbH; Darmstadt, Germany) 
was diluted in Opti-MEM® I Reduced Serum Medium (Gibco™, Life Technologies GmbH; 
Darmstadt, Germany). Control miRNA are unspecific and non-functional miRNA duplexes 
that mimic classical endogenous miRNA molecules. BLOCK-iT™ Alexa Fluor® Red 
Fluorescent Control coupled to Alexa Fluor® 555 was used to evaluate transfection 
efficiency via flow cytometry analysis (see 3.1.7). miRNA were stored at -20 °C until use. 
CD34LC were harvested between d8 and d12. Prior to transfection, cells were distributed 
into 24-well plates at 0.5 x 106 cells/0.5 mL per well. Cells were allowed to sediment for 1 h 
at 37 °C in the incubator. Cell numbers, Lipofectamine® RNAiMAX and miRNA 
concentrations were optimized to the CD34LC system. Lipofectamine® RNAiMAX / miRNA 
complexes were prepared based on the manufacturer’s guidelines. For 0.5 x 106 cells, 3 µL 
of Lipofectamine® RNAiMAX and 2.5 µL of each miRNA (10 µM) were separately diluted 
with 25 µL Opti-MEM® I Reduced Serum Medium. Diluted Lipofectamine® RNAiMAX was 
added to the diluted miRNA at a ratio of 1:1 (v/v). Lipofectamine® RNAiMAX / miRNA 
complexes were incubated for 5 min at room temperature. 50 µL of the complexes were 
dripped carefully on the cells of each well. The final transfection concentration was 50 nM 
per miRNA. Cells were incubated at 37 °C and 5 % CO2 for 24 h. The transfection efficiency 
of CD34LC was calculated by the amount of BLOCK-iT™ Alexa Fluor® Red Fluorescent 
Control - positive cells per all CD1a+ cells using flow cytometry analysis. Furthermore, all 
cells were analyzed by flow cytometry for surface molecules (see 3.1.7) and the CD1a+ 
enriched cell fraction (see 3.1.2) was examined by qPCR (see 3.2.8) and TaqMan® 
MicroRNA Assays (see 3.2.9). 
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3.1.7 Flow cytometry analysis 
Surface and intracellular immunofluorescence staining was employed in order to analyze 
CD34+ hematopoietic stem cell and CD1a+ cell enrichment as well as CD34LC phenotype 
and treatment effects. Staining antibodies used in this study are summarized in Table 5 and 
Table 6. Viability of the cells was examined by 7-AAD staining. Intracellular staining was 
performed according to the BD Cytofix/Cytoperm™ kit protocol (Beckton Dickinson GmbH; 
Heidelberg, Germany). Unless otherwise specified, 5 x 104 cells for surface staining and 
2 x 105 cells for intracellular staining, respectively, were stained successively with the 
indicated antibodies in a total volume of 100 µL FACS buffer at 4 °C for 25 min. Washing 
steps were executed in 1 mL FACS buffer (400 x g, 4 °C, 2 min). Cells were measured and 
analyzed utilizing a FACSCanto™ flow cytometer and FACSDiva™ software (Beckton 
Dickinson GmbH; Heidelberg, Germany) or FlowJo 7.6.1 software (FlowJo, LLC Data 
Analysis Software; Ashland, USA), respectively. For statistics, relative fluorescence index 
(rFI) was calculated as follows:  
 
(MFI = mean fluorescence intensity) 
 
3.1.8 Purity control of CD34+ hematopoietic stem cells and CD1a+ cell 
enrichment 
CD34+ enriched cells (see 3.1.4) were stained with 0.15 µg/mL PE-conjugated anti-
CD34 mAb or 2.5 µg/mL PE-conjugated anti-IgG1 for isotype control for 15 min at room 
temperature.  
CD1a+ enriched cells (see 3.1.2) were stained with an antibody mix containing IgG2a-APC, 
IgG1-RD1 and 7-AAD or CD14-APC, CD1a-RD1 and 7-AAD, respectively. The final 
concentrations of the respective antibodies for CD1a+ enriched cells are listed in Table 15. 
 
rFI   = 
MFI target   –   MFI isotype control 
MFI isotype control 
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3.1.9 Phenotypic characterization of CD34LC 
Expression of specific surface molecules was assessed by staining with unconjugated 
mouse monoclonal antibodies against Langerin (CD207), FcεRI, TLR2, CD80, CD83, CD86 
and MHC II. Unspecific mouse IgG2b was used as an isotype control antibody. FITC-
conjugated goat-anti-mouse IgG polyclonal antibody was used as secondary antibody. Free 
antigen-binding sites were blocked with 2.5 mg/mL mouse serum for 15 min at 4 °C. Finally, 
an antibody mix containing IgG2a-APC, IgG1-RD1 and 7-AAD or CD14-APC, CD1a-RD1 
and 7-AAD was added. Antibody concentrations used for surface staining are listed in Table 
15 below. 
 
Table 16  Antibody concentrations used for surface staining  
 
Antibody 
Stock 
concentration 
(mg/mL) 
Working 
concentration 
(µg/mL) 
Volume  
per test 
(µL) 
Final 
concentration 
(µg/mL) 
1s
t  
IgG2b, κ 1.0 50 5 2.5 
Langerin (CD207) 0.2 50 5 2.5 
FcεRIα 1.0 50 5 2.5 
TLR2* n.s. (1/10 dilution) 5 - 
CD83 0.2 50 5 2.5 
2n
d  Goat anti-mouse 
IgG, Fcγ 
1.0 50 5 2.5 
M
ix
 
IgG2a-APC 0.011 2.75 5 0.14 
CD14-APC 0.011 2.75 5 0.14 
IgG1-RD1 1.0 50 3 1.5 
CD1a-RD1 0.25 25 3 0.75 
7-AAD 1.0 50 2 1.0 
* Ascites preparation. Antibody concentration is not specified (n.s.).  
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Intracellular staining of transcription factors was performed with monoclonal antibodies 
against PU.1 followed by a FITC-conjugated goat-anti-mouse IgG polyclonal antibody. Free 
antigen-binding sites were blocked with 5 mg/mL mouse serum for 15 min at 4 °C. Finally, 
IgG2a-APC and IgG1-RD1 or CD14-APC and CD1a-RD1 antibody mixes were added (see 
Table 16).  
 
Table 17  Antibody concentrations used for intracellular staining 
 
Antibody 
Stock 
concentration 
(mg/mL) 
Working 
concentration 
(µg/mL) 
Volume  
per test 
(µL) 
Final 
concentration 
(µg/mL) 
1s
t  
IgG1, κ 1.0 50 10 5 
PU.1 2.0 50 10 5 
2n
d  Goat anti-mouse 
IgG, Fcγ 
1.0 50 10 5 
M
ix
 
IgG2a-APC 0.011 2.75 5 0.14 
CD14-APC 0.011 2.75 5 0.14 
IgG1-RD1 1.0 50 5 2.5 
CD1a-RD1 0.25 25 5 1.25 
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3.2 Molecular biological methods 
3.2.1 Determination of RNA and DNA concentrations and purity 
Concentrations and purity of nucleic acids were determined by using the spectrophotometer 
Synergy™ HT Multi-Mode Microplate Reader (BioTek Germany; Bad Friedrichshall, 
Germany). Concentrations were calculated by measuring RNA and DNA at the wave length 
λ = 260 nm. Purity was assessed by a λ260/280 ratio. Values were calculated with the Gen5™ 
software (BioTek Germany; Bad Friedrichshall, Germany). 2 µL of each nucleic acid and of 
nuclease-free water for RNA reference or 5 mM Tris/HCL buffer for DNA reference were 
measured. 
 
3.2.2 RNA isolation 
RNA of CD1a+ enriched cells (see 3.1.2) was extracted via the phenol/chloroform method 
utilizing TRIzol® reagent in accordance with the manufacturer’s protocol. RNA was 
resuspended in 25 µL nuclease-free water. DNA contaminations were removed using DNA-
free™ DNA Removal Kit (Ambion®, Life Technologies GmbH; Darmstadt, Germany) 
following the manufacturer’s instructions. RNA concentration and purity were evaluated (see 
3.2.1). RNA was reverse transcribed to cDNA for gene expression experiments (see 3.2.3), 
subject to TaqMan® MicroRNA Assays (see 3.2.9) or stored at -70 °C. 
 
3.2.3 Reverse transcription for gene expression experiments 
RNA was reverse transcribed into complementary DNA (cDNA). 1 µg RNA in 15.5 µL 
nuclease-free water was denaturated at 65 °C for 3 min and was then transferred directly on 
ice. 34.5 µL of a reverse transcription reaction mix (see Table 17) was added to RNA and 
incubated at 37 °C for 1 h. The reaction was stopped at 95 °C for 3 min. The cDNA volume 
was adjusted to 100 µL with nuclease-free water. cDNAs were kept on ice for immediate use 
in qPCR or were stored at -20 °C. 
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Table 18  Components of reverse transcription reaction mix 
Reagent Final concentration 
5x reverse transcription buffer 1x 
dNTP 4 µM (each) 
DTT 100 µM 
Random primer  2.4 ng/µL 
RNAsin 1 U/µL 
SuperScript™ Reverse Transcriptase 4 U/µL 
Final volume 34.5 µL 
 
 
3.2.4 Culture of bacterial cDNA clones 
cDNA clones provide the full length cDNA of interest incorporated in a vector and cloned 
into a host cell. In this study, cDNA clones from E. coli DH10B (genotype) carrying full length 
cDNA of the human FCER1A (see Table 8) were used for creating quantitative real-time 
PCR (qPCR) standard curves. For amplification, an inoculum of the bacterial glycerol stock 
was dropped into 4 mL liquid LB medium supplemented with 25 µg/mL chloramphenicol for 
selection. Aerobic growth occurred overnight at 37 °C in an orbital incubator shaker at 
170 rpm (Innova 4000, New Brunswick Scientific; Enfield, USA). The plasmid DNA was 
isolated (see 3.2.5).  
 
 
3.2.5 Isolation of plasmid DNA  
For plasmid isolation, 4 mL of bacterial overnight culture were harvested and processed 
using Invisorb® Spin Plasmid Mini Two (STRATEC Biomedical AG; Birkenfeld, Germany) 
according to the manufacturer’s instructions. Plasmid DNA was eluted with 75 µL 
5 mM Tris/HCL buffer (pH 8.5) and the concentration was determined as described in 3.2.1. 
The plasmids were subject to restriction enzyme digestion or were stored at -20 °C. 
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3.2.6 Restriction enzyme digestion 
Plasmid DNA was dissected via specific restriction enzyme digestion using EcoRI and XhoI 
(New England Biolabs; Frankfurt am Main, Germany) at 37 °C overnight following the 
manufacturer’s instructions. Products were analyzed by agarose gel electrophoresis (see 
3.2.7). 
 
3.2.7 Agarose gel electrophoresis 
For analysis of restriction enzyme digestion products or qPCR products, DNA was 
supplemented with Gel Loading Dye Blue, (6x) (New England Biolabs; Frankfurt am Main, 
Germany) and loaded on a 2 % agarose gel (w/v) containing 0.5 µg/mL ethidium bromid. 
Gels were run in 1x TAE buffer for 45 to 60 min between 90 and 110 volt. DNA was 
visualized by ImageQuant™ LAS 4000 (GE Healthcare; Chalfont St. Giles, Great Britain). 
Assessment of DNA fragment size was achieved by using Quick-Load® 2-Log DNA Ladder 
(0.1-10.0 kb) (New England Biolabs; Frankfurt am Main, Germany).  
 
3.2.8 Quantitative real-time PCR (qPCR) for gene expression experiments 
Gene expression is a strongly regulated process to control cellular activities, structure and 
responsiveness to the environment. Regulation of gene expression determines the amount 
and the timing of the synthesis of a gene product by the production of mRNA copies of the 
DNA sequence of a gene. qPCR has become a common technique to monitor gene 
expression in vitro and is based on standard end-point PCR. mRNA is reverse transcribed 
into cDNA and its amplification is measured after every cycle in “real-time” utilizing a 
fluorescence dye that intercalates and signals in double stranded DNA sequences (e.g. 
SYBR® Green) or a fluorescence labeled specific oligonucleotide probe that hybridizes with 
specific complementary DNA sequences (e.g. TaqMan® MicroRNA Assays, see 3.2.9). 
Accumulating amplification products lead to a gain of fluorescence intensity. When 
amplification-based signals exceed the background fluorescence the so called cycle 
threshold (Ct) has been reached. The Ct provides the number of cycles that are needed to 
rise above this threshold. 
In this study, iTag™ SYBR® Green Supermix with ROX™ was used. The mix includes 
SYBR® Green I (DNA-dye-complex absorption λmax = 497 nm; emission λmax = 520 nm) and 
42 Methods 
ROX™, a passive reference dye to normalize non-PCR-related fluctuations in fluorescence. 
StepOnePlus™ qPCR devices and StepOne™ Software v2.2.2 (Applied Biosystems® by 
Life Technologies GmbH; Darmstadt, Germany) were used to execute qPCR and to analyze 
the results. Amplicons are synthetically created DNA molecules mimicking the gene 
sequence specific for a certain primer pair. Amplicons and primers (see Table 7) were 
designed using Primer Express 3.0.1 software (Applied Biosystems® by Life Technologies 
GmbH; Darmstadt, Germany). Primer specificity for target genes was verified by 
NCBI/Primer-BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast/). 
Absolute quantification of the gene expression transcripts was achieved by using standard 
curves with a defined number of molecules of an amplicon calculated by its nanomolar 
quantity (indicated by the manufacturer) as follows: 
Molecules = x mole * 6.022 * 1023 
Amplicon stock solutions were adjusted to 3 x 1013 molecules/µL in nuclease-free water and 
stored at 4 °C. A standard dilution series was prepared in six concentrations reaching from 
3 x 108 molecules/µL to 3 x 10³ molecules/µL. Six standard curves of each primer pair were 
prepared. The mean Ct values were plotted against the concentrations (see Figure 2).  
The linear function of the regression line was used to calculate the amounts of molecules in 
cDNA samples:   
y   =  -1.522 * ln(X) + 40.251 
x   =  EXP((y-40.251)/(-1.522)) 
y = -1,522ln(x) + 40,251 
R² = 0,9999 
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Figure 2 Standard curve for actin. Dilution series of the amplicon for actin were prepared as described in the 
text. Mean Ct values of n=6 experiments were used to generate the regression line.  
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Results were normalized to 10³ molecules actin. The efficiency of primers was greater than 
80 %.  
The PCR master mix (see Table 18) was prepared in a volume of 9 µL and distributed into 
96-well plates. 1 µL of target cDNA (see 3.2.3), standard dilution series or nuclease-free 
water for a non-template control was added to the corresponding qPCR master mix. 
Samples and controls were measured in triplicates. Cycling conditions are summarized in 
Table 19. Melting curve analysis was performed to detect primer dimers or PCR byproducts.  
 
Table 19  Components of qPCR reaction mix for gene expression experiments. Forward and reverse 
primers were mixed together (1:1).  
Reagent Volume Final concentration 
iTaq™ SYBR® Green Supermix with ROX™ (2x) 5.0 µL 1x 
Primer mix (5 µM) 0.4 µL 0.2 µM 
cDNA / standard dilution / nuclease-free water 1.0 µL 10 % 
Nuclease-free water 3.6 µL - 
Final volume 10.0 µL  
 
 
 
Table 20  Thermal cycling conditions for qPCR for gene expression experiments (40 cycles) 
Step Duration Temperature 
Initial denaturation 10 min 95 °C 
Denaturation 15 s 95 °C 
Annealing and elongation 1 min 60 °C 
Melting curve  15 s +0.3 °C (until 95 °C) 
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3.2.9 TaqMan® MicroRNA Assays 
TaqMan® MicroRNA Assays (Life Technologies GmbH; Darmstadt, Germany) were 
performed to detect and quantify mature miRNA. Generally shortness of mature miRNA 
molecules (~ 22 nucleotides) leads to difficulties in the reverse transcription reaction with 
classical random hexamer or oligo-desoxythymidine primers. Therefore, the kit provides 
small miRNA-specific stem loop primers specific for the reverse transcription of mature 
miRNA only. The stem loop primer/miRNA complex leads to a 3’ extension of the 
synthesized cDNA that enables the hybridization of the reverse qPCR primer. The forward 
primer is complementary to the miRNA sequence. Amplification of cDNA in the qPCR is 
monitored using specific TaqMan® MGB probes containing a reporter dye (FAM™ dye) and 
a nonfluorescent quencher that suppresses the reporter fluorescence signal. The probe 
anneals specifically to complementary amplified DNA sequences between forward and 
reverse primer sites. In the next polymerization step, hybridized probes were cleaved by a 
hot start DNA polymerase and the reporter dye is separated from the probe. The 
fluorescence of the isolated reporter dye is no longer suppressed by the quencher molecule 
and can be detected by the qPCR device.  
 
TaqMan® MicroRNA Assays for miRNA-155-5p, miRNA-146a-5p and RNU48 (endogenous 
control) were executed following the manufacturer’s instructions. Reverse transcription PCR 
was performed with 10 ng total RNA isolated from TRIzol® samples (see 3.2.2) per 15 µL 
reaction utilizing the Mastercycler nexus gradient from Eppendorf (thermal cycling 
conditions: 30 min, 16 °C; 30 min, 42 °C; 5 min, 85 °C; ∞, 4 °C). The products were diluted 
1:1 (v/v) with nuclease-free water and were subject to TaqMan® qPCR reaction or stored 
at -20 °C for up to one week. qPCR was performed in triplicates with 1µL cDNA per 9 µL 
reaction mix (see Table 20). StepOne™ plus machine and StepOne™ Software v2.2.2 
(Applied Biosystems® by Life Technologies GmbH; Darmstadt, Germany) were used for 
processing (thermal cycling conditions see Table 21) and evaluation of TaqMan® MicroRNA 
Assays.  
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Table 21  Composition of qPCR reaction mix for TaqMan® MicroRNA Assays 
Component Volume per reaction Final concentration 
TaqMan® small RNA Assays (20x) 0.5 µL 1x 
TaqMan® Universal PCR MasterMix II (2x), no UNG 5.0 µL 1x 
Nuclease-free water 3.5 µL 3.5 % 
cDNA  1.0 µL 1.0 % 
Final volume 10.0 µL  
 
 
 
Table 22  Thermal cycling conditions for qPCR for TaqMan® MicroRNA Assays (40 cycles) 
Step Duration Temperature 
Initial denaturation 10 min 95 °C 
Denaturation 15 s 95 °C 
Annealing and elongation 1 min 60 °C 
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4 Results 
In contrast to epidermal LC from healthy subjects, those from AD express high levels of 
FcεRI (Bieber, de la Salle et al. 1992, Wollenberg, Kraft et al. 1996). AD skin is highly 
colonized with S.a. that can be recognized by TLR on LC. We could show that TLR2 
engagement decreases FcεRI in in vitro generated LC (Herrmann, Koch et al. 2013), but 
there are still open questions as to how FcεRI is regulated in detail. LC represent only 
~2-5 % of the cells in human skin. For LC research, sufficient human skin material is rarely 
available and LC isolation procedure easily activates these sensitive cells. Therefore a 
human cell model of in vitro generated CD34LC was chosen to investigate FcεRI regulation 
on human LC.  
 
 
4.1 In vitro generated CD34LC represent a suitable model to investigate 
human FcεRI regulation 
Prior to FcεRI investigation, in vitro generated CD34+ hematopoietic stem cell derived LC 
(CD34LC, see 3.1.4) have to be confirmed as a suitable cell model. Characteristically, LC 
differ from DC inter alia by the expression of Langerin. CD34LC are expected to express 
high levels of Langerin as well as CD1a. To begin with, an immature phenotype 
corresponding to LC in their epidermal environment is a prerequisite for stimulation 
experiments. Cell surface staining and flow cytometry analysis was performed to 
characterize CD34LC phenotype and maturation state. Cells were gated by their 
morphology, their viability by 7-AAD staining and by their CD1a expression (see Figure 3 A 
and B). CD1a+ cells were further analyzed for their Langerin and their CD83 expression (see 
Figure 3 C). 
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At day 8 to 12, in vitro generated CD34LC contained about 30 to 50 % of CD1a+ cells which 
expressed 50 % (± 25 %) Langerin. The immature phenotype of the cells was confirmed by 
low or absent CD83 surface expression.  
In conclusion, in vitro generated CD34LC cells were appropriate for further investigations by 
their LC-like phenotype and their immaturity. For FcεRI research, the receptor should be 
expressed on CD34LC, too. Therefore, FcεRI surface expression on CD34LC was verified 
next by flow cytometry analysis.  
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Figure 3 In vitro generated CD34LC show an immature LC phenotype. PBMC were isolated from cord blood 
using density gradient medium followed by CD34+ hematopoietic stem cell enrichment using MACS® Technology. 
CD34LC were generated by cultivating CD34+ hematopoietic stem cells for 8 to 12 days as described in methods. 
5 x 104 cells were stained with 7-AAD, anti-CD1a-RD1 and anti-CD14-APC to identify viable DC population (A, B). 
Antibodies against Langerin, CD83 (green) and IgG2b (grey) for isotype control were counterstained by FITC-
labeled goat anti-mouse IgG antibody (C). Cells were analyzed using Flow Cytometer FACSCanto™. Mean 
values ± SD of CD1a, Langerin and CD83 expression of n=8 experiments are depicted (B, C). (SD = standard 
deviation) 
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FcεRI showed a heterogeneous, donor-dependent surface expression. For further studies, 
only experiments with rFI higher than 1.5 were evaluated.  
 
In AD, skin is highly colonized with a plethora of bacteria which can be sensed by LC via 
PPR such as TLR. Before the link between TLR engagement and FcεRI regulation was 
examined, TLR2 expression on CD34LC was checked. 
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Figure 5 In vitro generated CD34LC express TLR2. Cells were generated as described in Figure 3. Viable 
CD1a+ cells were stained with anti-TLR2 (green) and anti-IgG2b (grey) for isotype control and were 
counterstained with FITC-labeled goat anti-mouse IgG. Cells were analyzed using Flow Cytometer FACSCanto™. 
Mean values ± SD of n=8 experiments are shown. (SD = standard deviation) 
0
5
10
15
20
rF
I 
FcεRI-FITC FcεRI 
%
 o
f m
ax
 
A B 
Figure 4 In vitro generated CD34LC express FcεRI. Cells were generated as described in Figure 3. Viable 
CD1a+ cells were stained with anti-FcεRI (green) and anti-IgG2b (grey) for isotype control and were 
counterstained with FITC-labeled goat anti-mouse IgG. Cells were analyzed using Flow Cytometer FACSCanto™. 
Mean values ± SD of n=8 experiments are shown. (SD = standard deviation) 
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Flow cytometry analysis revealed that TLR2 is expressed on CD34LC surface and may 
provide the basis for stimulation experiments with TLR2 ligands.  
In a next approach, the functionality of surface TLR2 was analyzed. This can be monitored 
by the TLR2-induced regulation of several costimulatory molecules. Here, the DC maturation 
marker CD83 as well as the C-C motif chemokine receptor 6 (CCR6) and the C-C motif 
chemokine receptor 7 (CCR7) were measured after TLR1/2 ligation with P3C. CCR6 is 
typically expressed in immature DC and is involved in the recruitment of DC to the 
inflammation sites. In contrast, CCR 7 is upregulated in activated DC and facilitates the 
migration to the lymph nodes.  
 
 
Figure 6 TLR2 engagement results in the maturation of in vitro generated CD34LC. CD34LC were generated 
as described in Figure 3. 1 x 106 cells/mL were left untreated (∅) or were treated with 1.0 µg/mL P3C for 24 h (A, 
B). 5 x 104 cells were stained against 7-AAD, CD1a-RD1, CD14-APC and CD83 (green) or IgG2b for isotype 
control (grey). Representative Histograms of CD83 expression are illustrated (A). Mean values ± SD of 
percentage of CD83 surface expression of untreated vs. treated cells are shown (B, n=8). Total RNA was 
prepared from TRIzol® samples of MACS® enriched CD1a+ cells. 1 µg of total RNA was used to reverse transcribe 
mRNA into cDNA. qPCR was performed in triplicates with 1 µL cDNA per reaction. CD83, CCR6 and CCR7 
mRNA was quantified using global standard curves of CD83, CCR6, CCR7 and of ACTB for normalization. Mean 
values ± SD of relative mRNA levels from n=8 experiments are shown (C). Statistical significance was assessed 
by paired sample Wilcoxon signed rank test using IBM SPSS Statistics 22 software. *p < 0.05; (SD = standard 
deviation) 
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TLR2 ligation resulted in strong and significant upregulation of CD83 surface protein and 
mRNA levels compared to untreated cells. CCR6 mRNA levels of treated cells decreased to 
less of 50 % compared to untreated cells. CCR7 was strongly induced. These findings 
revealed that in vitro generated CD34LC were functional LC which mature due to TLR2 
engagement. 
As evident from Figure 3 to Figure 6, in vitro generated CD34LC initially showed the 
required immature LC phenotype that expresses heterogeneous amounts of surface FcεRI. 
CD34LC maturation upon TLR2 engagement confirmed that the cells themselves and the 
TLR2 receptors were functional. 
In conclusion, in vitro generated CD34LC were comparable to LC of the skin. By virtue of 
their phenotype and of their functionality they provide a suitable cell model for investigations 
of FcεRI. 
 
4.2 FcεRI is downregulated upon stimulation of CD34LC with TLR ligands 
In AD, FcεRI is expressed on skin LC. Concomitantly, AD skin is highly colonized with S.a. 
(Boguniewicz and Leung 2010) that can be recognized by LC via TLR, especially via TLR2 
heterodimers (Biedermann 2006). To get more insight in the regulation of FcεRI upon 
different TLR engagement, CD34LC were stimulated with a set of TLR2 ligands. For ligand 
binding, TLR2 forms heterodimers with TLR1 and TLR6. TLR1/2 heterodimers recognize 
triacylated lipopeptides like P3C (Buwitt-Beckmann, Heine et al. 2006) while TLR2/6 
heterodimers interact with diacylated lipopeptides such as FSL-1 (Skabytska, Wolbing et al. 
2014) or with lipoteichoic acid (LTA). Here, CD34LC were stimulated with FSL-1, LTA and 
P3C and FcεRI surface expression was examined by flow cytometry analysis.  
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FcεRI surface expression was significantly reduced by the engagement of TLR2/6 
heterodimers with FSL-1 (-64 % ± 13 % of unstimulated) and LTA (-49 % ± 25 % of 
unstimulated), but most effectively after TLR1/2 stimulation with P3C (-82 % ± 10 % of 
unstimulated).  
The decrease of surface FcεRI can be preceded by a downregulation of FCER1 transcripts. 
On human LC, FcεRI builds a trimeric complex which is composed of one α- and two 
γ-chains (Kraft and Kinet 2007). Surface expression validation of the γ-chains by flow 
cytometry analysis was not practical because of the deficient epitopes of the almost 
intracellularly assembled chains. Therefore, qPCR analysis of FCER1A and FCER1G gene 
expression of FSL-1, LTA and P3C stimulated cells was performed to examine TLR-
mediated effects on both receptor chain transcripts.  
 
 
 
Figure 7 FcεRI surface expression is downregulated by the stimulation of CD34LC with TLR2 ligands. 
CD34LC were harvested between d8 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated with 
16.6 x 10-3 µg/mL FSL-1, 1.0 µg/mL LTA or 1.0 µg/mL P3C for 24 h. FcεRI cell surface expression of viable 
CD1a+ cells was analyzed by flow cytometry as described. Mean rFI values ± SD from n=7-8 experiments are 
shown. Statistical significance was assessed by paired-sample Wilcoxon signed rank test using IBM SPSS 
Statistics 22 software. *p < 0.05; (SD = standard deviation) 
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TLR-mediated stimulation of CD34LC resulted in a significant downregulation of FCER1A 
and FCER1G mRNA transcripts. FCER1A mRNA was hardly detectable upon stimulation 
with P3C. FCER1G transcripts were downregulated less strongly compared to the α-chain 
transcripts. In line with the results of the FcεRI cell surface expression (see Figure 7), the 
strongest reduction was obtained by the TLR1/2 ligand P3C (-84 % ± 10 % of unstimulated) 
followed by FSL-1 (-44 % ± 14 % of unstimulated) and LTA (-41 % ± 14 % of unstimulated).  
In summary, FcεRI was downregulated on the protein and on the transcriptional level by 
different TLR2 heterodimer ligands.  
 
So far, only synthetically derived or modified TLR2 ligands were tested, but skin harbors 
other TLR ligands, too. In vivo, skin immune cells have to cope additionally with complete 
bacterial synthesis and cell envelope products. Therefore, stimulation experiments with 
heat-killed bacterial strains of S.a. (Pansorbin®) and of S.p. (M49 vaccine POD 591) and the 
TLR4 ligand LPS derived from Escherichia coli (E. coli) were performed next. Based on the 
results above, P3C was taken as positive control. FcεRI expression of S.a., S.p, LPS and 
P3C treated cells was analyzed by flow cytometry and qPCR.  
  
Figure 8 FCER1A and FCER1G mRNA transcription levels decrease upon TLR-mediated stimulation of 
CD34LC. CD34LC were harvested between d9 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated 
with 16.6 x 10-3 µg/mL FSL-1, 1.0 µg/mL LTA or 1.0 µg/mL P3C for 24 h. qPCR was performed as described in 
Figure 6. FCER1A and FCER1G mRNA was quantified using global standard curves of FCER1A, FCER1G and 
of ACTB for normalization. Relative mRNA levels ± SD from n=8 experiments are shown. Statistical significance 
was assessed by paired-sample Wilcoxon signed rank test using IBM SPSS Statistics 22 software. *p < 0.05; (SD 
= standard deviation) 
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FcεRI expression was severely and significantly downregulated on protein and on 
transcriptional levels. FCER1A mRNA was decreased with LPS and P3C by 98 % (± 3 % 
and ± 1 %) and was almost undetectable after stimulation with S.a., S.p. and P3C. FCER1G 
mRNA was strongly downregulated after stimulation of CD34LC with LPS and the heat-killed 
Gram-positive bacteria. Here, the positive control P3C was significantly reduced, too. 
Taken together, stimulation of CD34LC with synthetically derived specific TLR ligands or 
with complete heat-killed bacteria resulted in all cases in a significant and strong 
downregulation of FcεRI on protein and mRNA level. How this decrease is regulated in 
CD34LC will be the aim of the next part of this work.  
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Figure 9 FcεRI is downregulated by stimulation of CD34LC with LPS and heat-killed bacteria. CD34LC were 
harvested between d8 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated with 0.1 µg/mL LPS, 
10 µL/mL S.a., 6.5 x 109 cells/mL S.p. or 1.0 µg/mL P3C for 24 h. FcεRI cell surface expression of viable CD1a+ 
cells was analyzed by flow cytometry as described. Mean values ± SD from n=5-7 experiments are shown (A). 
Representative histograms of FcεRI surface expression of untreated, LPS, S.a., S.p. and P3C treated cells are 
depicted in B. qPCR was performed as described in Figure 6. FCER1A and FCER1G mRNA was quantified using 
global standard curves of FCER1A, FCER1G and of ACTB for normalization. Relative mRNA levels ± SD from 
n=6-7 experiments are shown (C, D). Statistical significance was assessed by paired-sample Wilcoxon signed 
rank test using IBM SPSS Statistics 22 software. *p < 0.05; (SD = standard deviation) 
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4.3 FCER1A-associated transcription factor PU.1 is decreased after 
TLR-mediated stimulation of CD34LC 
As obtained from the data above, stimulation of CD34LC with several TLR ligands resulted 
in a significant reduction of FcεRI on protein and on transcriptional levels. In the following 
approach, the transcriptional regulation of the FcεRI α-chain will be scrutinized.  
Transcription factors are regulatory elements that control the synthesis of a gene transcript 
by binding to a gene’s promotor region. They can operate as transcriptional enhancers or 
repressors. Data obtained from the literature describe that the transcription factors PU.1, 
Yy1 and Gata-1 as well as Hmgb1, Hmgb2 and Sp1 enhance FCER1A gene expression by 
binding to its proximal promotor region, while Elf-1 acts as a transcriptional repressor 
(Kanada, Nakano et al. 2008, Nishiyama, Hasegawa et al. 2002). First, the expression of 
these FCER1A-associated transcription factors in unstimulated FcεRI+ CD34LC was 
analyzed by qPCR.  
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Figure 10 Transcription factor PU.1 is predominantly expressed in CD34LC. CD34LC were harvested 
between d8 and d12. qPCR was performed as described in Figure 6. mRNA levels of the indicated transcription 
factors were quantified using global standard curves of the respective transcription factor and of ACTB for 
normalization. Mean values of relative mRNA levels ± SD from n=8 experiments are shown.  
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The FCER1A related transcription factor PU.1 showed the highest mRNA expression level 
with a relative mRNA expression of 44 (± 14 SD) molecules per 10³ molecules actin. ELF1, 
HMGB1, HMGB2, SP1 and YY1 were only weakly expressed. GATA1 mRNA was not 
detected (data not shown). This indicated that PU.1 may be the most influencing 
transcription factor in FcεRI regulation in CD34LC. For further evidence, the indicated 
transcription factors were analyzed by qPCR in FSL-1, LTA and P3C stimulated CD34LC, 
too.  
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Figure 11 EFL1, PU.1, YY1, HMGB1 and HMGB2 are downregulated upon TLR2-mediated stimulation of 
CD34LC. CD34LC were harvested between d8 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated 
with 16.6 x 10-3 µg/mL FSL-1, 1.0 µg/mL LTA or 1.0 µg/mL P3C for 24 h. qPCR was performed as described in 
Figure 6. mRNA levels of the indicated transcription factors were quantified using global standard curves of the 
respective transcription factor and of ACTB for normalization. Mean values of relative mRNA levels ± SD from 
n=7-8 experiments are shown. Statistical significance was assessed by paired-sample Wilcoxon signed rank test 
using IBM SPSS Statistics 22 software. *p ≤ 0.05; (SD = standard deviation) 
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PU.1, HMGB1 and HMGB2 mRNA expression was significantly and most strongly 
decreased after stimulation with P3C followed by FSL-1 and LTA. ELF1 and YY1 were 
downregulated to a lesser extent after TLR2 engagement. SP1 mRNA was not changed by 
the TLR-mediated stimulation of CD34LC.  
To evaluate the relationship between the expression of FcεRI and its respective transcription 
factor on CD34LC, Pearson correlations with FCER1A of untreated, FSL-1, LPS and P3C 
treated cells were analyzed.  
 
Figure 12 Expression of ELF1, PU.1, YY1, HMGB1 and HMGB2 correlates with FCER1A mRNA expression. 
CD34LC were harvested between d8 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated with 
16.6 x 10-3 µg/mL FSL-1, 1.0 µg/mL LTA or 1.0 µg/mL P3C for 24 h. qPCR was performed as described in Figure 
6. mRNA levels of the indicated transcription factors were quantified using global standard curves of the 
respective transcription factors and of ACTB for normalization. Relative mRNA levels of FCER1A were plotted 
against relative mRNA levels of indicated transcription factors. Statistical analyses of correlations are summarized 
in Table 22. Pearson correlations blots were generated using IBM SPSS Statistics 22 software. 
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Pearson correlation coefficients and significances of data depicted in Figure 12 were 
calculated and summarized in the following table. 
 
Table 23 Summary of Pearson correlations and significances as depicted in Figure 12. Pearson correlation 
coefficients and significances were calculated using IBM SPSS Statistics 22 software. 
    ELF1 PU.1 YY1 HMGB1 HMGB2 SP1 
FCER1A Pearson correlation 0.560** 0.682** 0.513** 0.649** 0.537** 0.082 
 Sig. (2-tailed) 0.002 0,000 0.006 0.000 0.004 0.685 
  N 27 27 27 27 27 27 
** Correlation significance at level 0.01 (2-tailed).   
   ** Correlation significance at level 0.05 (2-tailed).           
 
 
The mRNA expression of the FCER1A-associated transcription factors PU.1, EFL1, YY1, 
HMGB1 and HMGB2 positively correlated with the FCER1A transcripts. PU.1 achieved the 
highest correlation coefficient with 0.682. Significances were obtained for all transcription 
factors except SP1 that neither correlated with FCER1A. 
 
According to Figure 9, FcεRI expression decreased significantly with LPS and the heat killed 
bacteria, too. Therefore, FcεRI-associated transcription factors were examined again by 
qPCR after treatment of CD34LC with LPS, S.a., S.p. and P3C. 
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Only the transcription factor PU.1 was downregulated significantly by all tested stimulants. 
The expression of YY1 was diminished equally by LPS, S.p. and P3C. HMGB1 expression 
was decreased significantly by LPS, S.p. and P3C, while HMGB2 showed a significant 
reduction only with P3C. Overall, HMGB1 and HMGB2 exhibited a very heterogeneous 
expression. Less regulatory effects on mRNA levels were attained for the transcription 
factors ELF1 and SP1.  
In summary, PU.1 was the only transcription factor that decreased significantly with all 
investigated stimuli.  
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Figure 13 PU.1 is significantly decreased upon stimulation of CD34LC with LPS, S.a. and S.p.. Cells were 
harvested between d8 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated with 0.1 µg/mL LPS, 
10 µL/mL S.a., 6.5 x 109 cells/mL S.p. or 1.0 µg/mL P3C for 24 h. qPCR was performed as described in Figure 6. 
mRNA levels of the indicated transcription factors were quantified using global standard curves of the respective 
transcription factor and of ACTB for normalization. Relative mRNA levels ± SD from n=6-7 experiments are 
shown. Statistical significance was assessed by paired-sample Wilcoxon signed rank test using IBM SPSS 
Statistics 22 software. * p < 0.05; (SD = standard deviation) 
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Again, Pearson correlations of FCER1A and the indicated transcription factors were 
analyzed in untreated, LPS, S.a., S.p. and P3C treated CD34LC.  
 
 
 
Pearson correlation coefficients and significances of data depicted in Figure 14 were 
calculated and summarized in the following table. 
 
Figure 14 Expression of ELF1, PU.1, YY1, HMGB1 and HMGB2 correlates with FCER1A mRNA expression. 
CD34LC were harvested between d8 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated with 
0.1 µg/mL LPS, 10 µL/mL S.a., 6.5 x 109 cells/mL S.p. or 1.0 µg/mL P3C for 24 h. qPCR was performed as 
described in Figure 6. mRNA levels of the indicated transcription factors were quantified using global standard 
curves of the respective transcription factor and of ACTB for normalization. Relative mRNA levels of FCER1A 
were plotted against relative mRNA levels of the indicated transcription factor. Statistical analyses of correlations 
are summarized in Table 23. Pearson correlations blots were generated using IBM SPSS Statistics 22 software. 
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Table 24 Summary of Pearson correlations and significances as depicted in Figure 14. Pearson correlation 
coefficients and significances were calculated using IBM SPSS Statistics 22 software. 
    ELF1 PU.1 YY1 HMGB1 HMGB2 SP1 
FCER1A Pearson correlation 0.396** 0.822** 0.446** 0.799** 0.700** 0.493 
 Sig. (2-tailed) 0.025 0.000 0.010 0.000 0.000 0.004 
  N 32 32 32 32 32 32 
** Correlation significance at level 0.01 (2-tailed).      ** Correlation significance at level 0.05 (2-tailed).         
 
The correlation analysis revealed the highest correlation of FCER1A with PU.1 (0.822) 
followed by HMGB1 (0.799) and HMGB2 (0.700). Correlation coefficients of ELF1, YY1 and 
SP1 were less than 0.5.  
 
 
Taken together so far, PU.1 showed the highest expression of all FCER1A related 
transcription factors investigated in this study and may therefore contribute most strongly to 
the regulation of FcεRI. Stimulation of CD34LC with TLR2 and TLR4 ligands as well as with 
heat-killed bacteria resulted in a significant decrease of PU.1 which correlated with the 
FCER1A mRNA expression. Therefore, PU.1 protein expression was further investigated by 
intracellular staining with anti-PU.1 and flow cytometry to analyze the expression of the 
transcription factor on protein level after TLR2 stimulation of CD34LC with P3C. 
  
Results  61 
 
 
The expression of PU.1 protein level was reduced up to one third after TLR1/TLR2 
heterodimer engagement with P3C. These results were in line with the reduced PU.1 mRNA 
expression level. 
 
Comparing the FCER1A-associated transcription factor investigated in this study, PU.1 was 
most strongly expressed in CD34LC. PU.1 mRNA expression was significantly 
downregulated after engagement of TLR1/2 (P3C), TLR2/6 (FSL-1, LTA), TLR4 (LPS) and 
with preparations of S.a. and S.p.. On protein level, PU.1 was reduced up to 30 % after 
stimulation of CD34LC with P3C. Furthermore, PU.1 expression correlated with the 
expression of FCER1A. In sum, among the here investigated transcription factors, PU.1 may 
contribute most strongly to the regulation of FcεRI in CD34LC. It will be elucidated in the 
next part of this work how PU.1 itself is regulated in CD34LC upon stimulation. 
 
  
Figure 15 Intracellular PU.1 expression is reduced after TLR-mediated stimulation. CD34LC were harvested 
between d8 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated with 1.0 µg/mL P3C for 24 h. 
2 x 105 cells were prepared for intracellular staining according to the BD Cytofix/Cytoperm™ kit protocol. Viable 
CD1a+ cells were stained with anti-PU.1 and followed by FITC-labeled goat anti-mouse IgG. Intracellular PU.1 of 
n=5 experiments was analyzed by flow cytometry using Flow Cytometer FACSCanto™ (A). Representative 
histograms of intracellular PU.1 expression of untreated (grey line) and P3C-treated cells (blue line) are depicted 
in B (Isotype control = grey tinted). 
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4.4 Regulation of the transcription factor PU.1 
The results obtained above suggest that PU.1 is involved in the regulation of the expression 
of FcεRI. PU.1 expression itself can be controlled on different levels. First, the transcription 
of PU.1 is regulated by several - in part tissue specific - transcription factors or 
transcriptional enhancers, as described e.g. for CCAAT-enhancer-binding proteins (C/EBP), 
c-jun or Runx1 (Behre et al. 1999, Leddin, Perrod et al. 2011). The latter is only expressed 
in early myeloid cell development and will not be included in this study. Secondly, post-
transcriptional mechanisms such as protein-protein interactions like those of Gata-1 and 
PU.1, phosphorylation status of the PU.1 protein or PU.1 mRNA binding by micro-RNA 
(miRNA) can influence the protein function and the protein formation. Additionally, recent 
studies revealed that the cytokine interleukin 33 (IL-33) enhances PU.1 expression in 
murine mast cells (Ito et al. 2015) most probably by using one of the above mentioned 
regulatory mechanisms.  
 
4.4.1 C/EBPα and Gata-1 are not involved in the regulation of the 
transcription factor PU.1 in CD34LC 
The function of C/EBPα is controversly discussed in the literature. In murine myeloid cells, 
C/EPBα is described to bind to an upstream regulatory element of the PU.1 promotor and 
thereby promotes PU.1 auto-activation through opening chromatin structures (Leddin, 
Perrod et al. 2011). Former studies revealed that C/EBPα competes with c-Jun, a co-
activator of PU.1, and thereby inhibits PU.1 transcription in myeloid U937 cells (Reddy, 
Iwama et al. 2002).  
Moreover, protein-protein interactions as described for the Gata-1 zink finger domains and 
PU.1 Ets domains can negatively influence the DNA binding capacity of PU.1 (Nerlov, 
Querfurth et al. 2000), too.  
Here, the expression of C/EBPA and GATA-1 in FSL-1, LTA and P3C treated CD34LC was 
examined by qPCR. 
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CEBPA was only negligibly expressed in CD34LC and showed a significant regulation only 
with P3C. GATA1 mRNA was not detectable in any case (data not shown).  
 
Recent studies reported an upregulation of PU.1 by IL-33 in murine mast cells (Ito, Egusa et 
al. 2015). Here, IL-33 treated CD34LC (kind gift of Tim Stroisch and Dr. Takanobu Kan) 
were analyzed for their PU.1 and additionally for FCER1A and FCER1G expression.  
Neither PU.1 nor FCER1A and FCER1G mRNA levels were affected by IL-33 treatment.  
Figure 16 CEBPA is only marginally expressed in CD34LC. CD34LC were harvested between d8 and d12. 
1 x 106 cells/mL were left untreated (∅) or were treated with 16.6 x 10-3 µg/mL FSL-1, 1.0 µg/mL LTA or 1.0 µg/mL 
P3C for 24 h. qPCR was performed as described in Figure 6. mRNA levels of CEBPA were quantified using global 
standard curves of CEBPA and of ACTB for normalization. Mean values of relative mRNA levels ± SD from n=6-7 
experiments are shown. Statistical significance was assessed by paired-sample Wilcoxon signed rank test using 
IBM SPSS Statistics 22 software. *p ≤ 0.05; (SD = standard deviation) 
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Figure 17 IL-33 has no influence on PU.1 expression. CD34LC were harvested between d8 and d12. 
1 x 106 cells/mL were left untreated (∅) or were treated with 10 ng/mL IL-33 for 24 h. qPCR was performed as 
described in Figure 6. Mean values of relative mRNA levels ± SD from n=9 experiments are shown. Statistical 
significance was assessed by paired-sample Wilcoxon signed rank test using IBM SPSS Statistics 22 software. *p 
≤ 0.05; (SD = standard deviation) 
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The lack of GATA1 expression and the very low C/EBPA mRNA levels in CD34LC renders it 
unlikely that these transcription factors are involved in PU.1-mediated regulation of FcεRI in 
CD34LC. IL-33 neither emerged as a candidate for PU.1 regulation in these cells. Therefore, 
in the next step the contribution of miRNA to PU.1 regulation in CD34LC was investigated.  
 
 
4.4.2 The transcription factor PU.1 is regulated by miRNA-155  
Since PU.1 regulation is not controlled by the above investigated factors in CD34LC, PU.1-
targeting miRNA-155 was analyzed.  
In general, miRNA are short single stranded regulatory nucleic acids. They are highly 
conserved in animals and plants and play a pivotal role in post-transcriptional modulation of 
gene expression by binding target mRNA. miRNA-155 was reported to down-regulate PU.1 
expression by binding to the 3’ UTR of PU.1 mRNA (Martinez-Nunez, Louafi et al. 2009). 
Another miRNA, namely miRNA-146a, plays a pivotal role in desensitization against TLR 
dependent stimuli (Jurkin, Schichl et al. 2010, Nahid, Pauley et al. 2009) and is constitutively 
expressed in DC subsets. Since CD34LC were treated with several TLR ligands, 
miRNA-146a expression was analyzed in this work, too. 
Here, TaqMan® MicroRNA Assay of miRNA-155 and miRNA-146a was performed to 
analyze the expression of those miRNA in FSL-1, LTA, LPS, S.a., S.p. and P3C treated 
CD34LC.  
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Taqman® MicroRNA Assays of miRNA-155 revealed a strong and significant upregulation of 
miRNA-155 after stimulation of CD34LC with specific TLR ligands. TLR1/TLR2 heterodimer 
engagement with P3C caused the strongest effect with mean values up to 13-fold, followed 
by FSL-1 (7.1 ± 3.2 -fold) and LTA (4.4 ± 2.2 -fold) for TLR2/TLR6 engagement. Among the 
heat-killed bacteria, S.p. was the most powerful inducer of miRNA-155 (17.2 ± 12.7 -fold). 
miRNA-146a was less strongly induced after TLR1/TLR2, TLR2/TLR6 and TLR4 
engagement as well as after stimulation with S.a. and S.p..  
Figure 18 miRNA-155 is induced by stimulation of CD34LC with TLR ligands and heat-killed bacteria. 
CD34LC were harvested between d8 and d12. 1 x 106 cells/mL were left untreated (∅) or were treated with 
16.6 x 10-3 µg/mL FSL-1, 1.0 µg/mL LTA or 1.0 µg/mL P3C (A, C), 0.1 µg/mL LPS, 10 µL/mL S.a., 6.5 x 109 
cells/mL S.p. or 1.0 µg/mL P3C (B, D) for 24 h. Total RNA preparation was performed as described in Figure 6. 
10 ng RNA were subject to Taqman® MicroRNA Assays of miRNA-155 (A, B) and miRNA-146a (C, D). Boxplots of 
relative miRNA levels ± SD from n=6-7 experiments and statistical significances assessed by paired sample 
Wilcoxon signed rank test were generated using IBM SPSS Statistics 22 software. ͦ =outlier; *p < 0.05; (SD = 
standard deviation) 
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To evaluate the relationship between the expression of miRNA-155 and miRNA-146a, 
respectively, and PU.1 as well as FcεRIα, Pearson correlation analyses for miRNA-155, 
miRNA146a, PU.1 and FCER1A of untreated, FSL-1, LTA, LPS, S.a., S.p. and P3C treated 
CD34LC were performed.  
  
 
 
Pearson correlation coefficients and significances of data depicted in Figure 19 were 
calculated and summarized in the following table. 
 
  
Figure 19 Expression of miRNA-155, but not miRNA-146a correlates with PU.1 and FCER1A mRNA. Cells 
were treated as described in Figure 18. ΔΔCT values of PU.1, FCER1A were plotted against miRNA-155 and 
miRNA-146a or against each other. Statistical analyses of correlations are summarized in Table 24. Pearson 
correlation plots were generated using IBM SPSS Statistics 22 software. 
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Table 25 Summary of Pearson correlations and significances as depicted in Figure 19. Pearson correlation 
coefficients and significances were calculated using IBM SPSS Statistics 22 software. 
  miRNA-155 PU.1 FCER1A miRNA-146a 
miRNA-155 Pearson correlation 1 -0.688
** -0.807** 0.476** 
Sig. (2-tailed)  0.000 0.000 0.000 
N 55 55 52 55 
PU.1 Pearson correlation -0.688
** 1 0.790** -0.020 
Sig. (2-tailed) 0.000  0.000 0.883 
N 55 58 55 55 
FCER1A Pearson correlation -0.807
** 0.790** 1 -0.239 
Sig. (2-tailed) 0.000 0.000  0.088 
N 52 55 55 52 
** Correlation significance at level 0.01 (2-tailed). 
** Correlation significance at level 0.05 (2-tailed). 
 
Correlation analysis of miRNA-155, PU.1 and FCER1A mRNA expressions revealed 
significant negative correlations between miRNA-155 and PU.1 mRNA as well as FCER1A 
mRNA. As expected, a significant positive correlation was found between mRNA of PU.1 
and FCER1A. miRNA-146a expression did not correlate with PU.1 or FCER1A.  
 
 
In conclusion, the data above revealed that miRNA-155 was strongly induced upon 
stimulation of CD34LC with several TLR ligands, while PU.1 and FcεRI decreased in inverse 
proportion. Thus, miRNA-155 seems to regulate PU.1 and indirectly FcεRI expression in a 
CD34LC activation-dependent manner. The regulation of PU.1 by miRNA-155 will be proved 
by transfection experiments with pre-miRNA-molecules in CD34LC.  
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4.5 Ectopic miRNA-155 is sufficient for downregulation of PU.1 and FcεRI 
As observed from Figure 18, miRNA-155 is induced by the stimulation of CD34LC with 
several TLR ligands or heat-killed bacteria. Transcription factor PU.1 and FcεRI were 
downregulated in line with miRNA-155 upregulation. Transfection of CD34LC with 
synthetically derived pre-miRNA molecules for miRNA-155 and miRNA-146a was 
established to evaluate miRNA function independent of stimulation conditions. Synthetically 
derived pre-miRNA are released into the cytoplasm of the target cells where they are 
transformed into mature and functional miRNA molecules using the endogenous pre-miRNA 
processing pathway. 
 
4.5.1 miRNA transfection is successfully established in CD34LC 
The first challenge in transfection experiments is to get the desired product into the chosen 
cells. In particular, transfection of immature CD34LC is tricky because of their capacity to 
mature rapidly upon several stimuli. Therefore a mild transfection method with lipid particles 
was selected and the transfection efficiency (TE) was proved in a first step.  
 
TE was examined by flow cytometry analysis. CD34LC were transfected with Block-It-
AF555, an unspecific miRNA coupled to an AlexaFluor®-555 fluorochrome. To exclude 
others than CD1a+ cells, the efficiency was calculated only by the percentage of Block-It-
AF555+/CD1a+ cells in relation to all CD1a+ cells (see equation). 
 
 
Block-IT-AF555+ / CD1a+ 
All CD1a
+
 
TE   = 
Figure 20 Equation for the calculation of the transcription efficiency in CD1a+ CD34LC. Block-ItAF555 -
transfected cell (see 3.1.6) were gated on their CD1a+ cell population. The ratio of Block-It-AF555+/CD1a+ to all 
CD1a+ cells was calculated. 
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To evaluate the kinetics of CD34LC transfection with Block-It-AF555, TE was analyzed by 
flow cytometry prior to transfection (0 h) as well as 2, 4 and 24 h after transfection.  
 
 
The time course of CD34LC transfection with Block-It-AF555 showed the highest TE within 
2 h and 4 h. After 24 h 50 % of all CD1a+ were still Block-It-AF555+. Since Block-It-AF555 is 
no pre-miRNA and will not be processed by the cells’ machinery, it is just an indication of 
effective transfection. In summary, transfection experiments of this study showed 
heterogeneous TE reaching from 14 % to 50 % after 24 h. 
 
For further validations, Taqman® MicroRNA Assays were performed to confirm specificity 
and quantity of every individual transfection with specific pre-miRNA. First, kinetics of 
specific pre-miRNA-155 transfection should provide information of the evolving time and the 
stability of mature miRNA in the cells. Therefore, CD34LC were transfected with 
pre-miRNA-155 and with Block-It-AF555 for 0.5, 1, 2, 4 and 24 h and were analyzed by 
Taqman® MicroRNA Assays for miRNA-155 at every time point.  
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Figure 21 Transfection efficiency of CD34LC. CD34LC were harvested between d8 and d12. 0.5 x 106 cells/mL 
were transfected with 50 nm Block-It-AF555 fluorescence oligo for 2, 4 and 24 h. Cells were stained with anti-
CD1a-APC and were subject to flow cytometry analysis using Flow Cytometer FACSCanto™.  
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Time course experiments of pre-miRNA-155 transfection in CD34LC revealed that the 
amounts of detected miRNA-155 via Taqman® MicroRNA Assays reached a very high peak 
after 4 h and were stable for at least 24 h. Transfection with Block-It-AF555 was used as 
control miRNA and for calculation of the transfection efficiency by flow cytometry analysis 
(see Figure 20). Block-It-miRNA transfection showed no effect on miRNA-155 expression. 
Next, the specifity of pre-miRNA-155 and pre-miRNA-146a transfection was checked by 
Taqman® MicroRNA Assays.   
Figure 22 Ectopic miRNA-155 is stable up to 24 h. CD34LC were harvested between d8 and d12. 
0.5 x 106 cells/mL were transfected with 50 nm pre-miRNA-155 or 50 nm Block-It-AF555 for 0.5, 1, 2, 4 and 24 h. 
Total RNA was prepared as described in Figure 6. 10 ng RNA were subject to Taqman® MicroRNA Assays for 
miRNA-155. 
Figure 23 Transfections of pre-miRNA-155 and pre-miRNA-146a are specific. CD34LC were harvested 
between d8 and d12. 0.5 x 106 cells/mL were transfected with control miRNA (Ctr.), 50 nm pre-miRNA-155 
(Pre-155), 50 nm pre-miRNA-146a (Pre-146a) or with Lipofectamine only (mock) for 24 h. RNA preparation was 
performed as described in Figure 6. 10 ng RNA were subject to Taqman® MicroRNA Assays of miRNA-155 (A) 
and miRNA-146a (B). Boxplots of n=7-10 (mock n=5) experiments were created using IBM SPSS Statistics 22 
software.  
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Transfections with pre-miRNA-155 and pre-miRNA-146a showed a high increase of mature 
miRNA-155 respective miRNA-146a. To exclude side effects and to confirm the specificity of 
the transfections, the primers of a respective Taqman® MicroRNA Assay were used for both 
pre-miRNA transfections. 
 
As evident from Figure 21 to Figure 23, transfection of CD34LC with pre-miRNA-155 and 
pre-miRNA-146a was established successfully. Taqman® MicroRNA Assays of both miRNA 
confirmed a successful, specific and sufficient transfection of CD34LC with pre-miRNA-155 
and pre-miRNA-146a. Therefore, basic requirements for the following analysis of the 
influence of miRNA-155 on PU.1 and FcεRI in CD34LC were met. 
 
4.5.2 miRNA-155 down-regulates PU.1 and FcεRI 
miRNA-155 has been validated for binding PU.1 mRNA in human DC (Martinez-Nunez, 
Louafi et al. 2009). In the previous section, pre-miRNA transfection in CD34LC was 
successfully established. Next, the influence of ectopic miRNA-155 on PU.1 and 
subsequently FcεRI expression will be investigated.  
CD34LC were transfected with pre-miRNA-155 and pre-miRNA-146a. Expression of PU.1 
and FcεRI was analyzed by qPCR and flow cytometry.  
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Transfection of CD34LC with miRNA-155 precursor molecules resulted in a significant 
downregulation of PU.1 and of FcεRI. Precursors of miRNA-146a did not influence PU.1 nor 
FcεRI expression. FCER1G tended to decrease only with miRNA-155, but this was not 
significant. However, FcεRI decreased after miRNA-155 transfection most likely due to the 
downregulation of the FCER1A transcript. This may be caused by a miRNA-155 – induced 
PU.1 reduction. 
  
Figure 24 PU.1 and FCER1A are downregulated by ectopic miRNA-155. CD34LC were harvested between d8 
and d12. 0.5 x 106 cells/mL were transfected with 50 nm pre-miRNA-155 (pre-miR-155), 50 nm pre-miRNA-146a 
(pre-miR-146a) or 50 nm control miRNA (Ctr.) for 24 h. qPCR was performed as described in Figure 6. FcεRI cell 
surface expression of viable CD1a+ cells was analyzed by flow cytometry as described. Mean values ± SD of 
relative miRNA levels from n=9-10 experiments are shown. Statistical significance was assessed by 
paired-sample Wilcoxon signed rank test using IBM SPSS Statistics 22 software. *p ≤ 0.05; (SD = standard 
deviation) 
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Finally, other FcεRI related transcription factors were analyzed by qPCR after pre-
miRNA-155 and pre-miRNA-146a transfection of CD34LC. 
 
 
 
After transfection of CD34LC with pre-miRNA-155, FcεRIα-associated transcription factors 
ELF1, HMGB1, HMGB2 and SP1 showed significant decreases along with PU.1 and FcεRI 
downregulation. This suggests a contribution of those transcription factors to the regulation 
of FcεRI in CD34LC. To elucidate the relationship between ectopic miRNA-155 and 
miRNA-146a, Pearson correlation analysis was performed. 
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Figure 25 EFL1, HMGB1, HMGB2 and SP1 decrease upon transfection with ectopic miRNA-155. CD34LC 
were harvested between d8 and d12. 0.5 x 106 cells/mL were transfected with 50 nm pre-miRNA-155 (pre-
miR-155), 50 nm pre-miRNA-146a (pre-miR-146a) or 50 nm control miRNA (Ctr.) for 24 h. qPCR was performed 
as described in Figure 6. Mean values ± SD of relative miRNA levels from n=9-10 experiments are shown. 
Statistical significance was assessed by paired-sample Wilcoxon signed rank test using IBM SPSS Statistics 22 
software. *p ≤ 0.05; (SD = standard deviation) 
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Table 26 Summary of Pearson correlations and significances of FCER1A, FCER1G and denoted 
transcription factors after pre-miRNA transfections. Pearson correlation coefficients and significances were 
calculated using IBM SPSS Statistics 22 software.  
                    
    FCER1A FCER1G ELF1 PU.1 YY1 HMBG1 HMGB2 SP1 
miRNA-155 Pearson correlation -0.558** -0.490* -0.449* -0.440* -0.354 -0.347 -0.491* -0.690** 
 
Sig. (2-tailed) 0.006 0.018 0.032 0.036 0.098 0.104 0.017 0.000  N 23 23 23 23 23 23 23 23 
miRNA-146a Pearson correlation 0.101 0.100 0.082 0.104 -0.095 -0.046 -0.011 0.141 
 
Sig. (2-tailed) 0.6634 0.6660 0.7237 0.6547 0.6816 0.8422 0.9631 0.5419  N 21 21 21 21 21 21 21 21 
** Correlation significance at level 0.01 (2-tailed).     ** Correlation significance at level 0.05 (2-tailed).     
           
Pearson correlation analysis revealed significant negative correlations for miRNA-155 with 
FCER1A, FCER1G, PU.1 and the transcription factors ELF1, HMGB2 and SP1. 
miRNA-146a did not correlate with FCER1A or any of the transcription factors investigated 
here. The results implicate again that miRNA-155 is participating in FcεRI regulation via 
PU.1 targeting. Other FcεRIα−associated transcription factors may contribute to the 
downregulation of FcεRI.  
To conclude, the induction of miRNA-155 with ectopic precursor molecules proved to be a 
sufficient model to investigate FcεRI function. In CD34LC, PU.1 and subsequently FcεRI 
were downregulated significantly by ectopic miRNA-155, but not by miRNA-146a. 
Downregulation of FcεRI was most likely caused by the decrease of FCER1A, since 
FCER1G was not changed significantly by miRNA-155 nor by miRNA-146a. Even if there is 
no evidence for being a target of miRNA-155 so far, ELF1, HMBG2, and SP1 expression 
changed significantly in pre-miRNA-155 transfected CD34LC, too. 
  
Results  75 
4.6 Summary of the results 
In this work, an in vitro generated CD34+ stem cell-derived Langerhans cell model (CD34LC) 
was validated for the investigation of FcεRI regulation upon activation of the cells. FcεRI was 
downregulated after engagement of CD34LC with a set of TLR ligands and inactivated 
bacterial strains of S.a. and S.p.. Among the investigated FcεRIα-related transcription 
factors, PU.1 was the most predominant one. PU.1 was downregulated significantly with all 
tested stimuli and its expression correlated with those of FCER1A. Concerning the 
regulation of PU.1 itself, miRNA-155 emerged as a post-transcriptional regulator of PU.1, 
while other regulatory elements such as C/EBPα, Gata-1 and IL-33 could be excluded in 
CD34LC. miRNA-155 was strongly induced upon stimulation of CD34LC, while PU.1 as well 
as FcεRI expressions decreased in inverse proportion. miRNA-146a was only weakly 
affected and lacked any influence on PU.1 or FcεRI expression. To confirm the regulatory 
influence of miRNA-155 on PU.1 and in succession on FcεRI expression independently of 
TLR activation, transfection experiments with pre-miRNA-155 and pre-miRNA-146 were 
established in CD34LC. Here, ectopic miRNA-155, but not miRNA-146, was sufficient to 
significantly down-regulate PU.1 and subsequently FcεRIα independent of any stimuli.  
Finally, this study uncovered that TLR signaling is linked to the regulation of FcεRI via 
miRNA-155 and PU.1 in CD34LC.  
 
 
   
  
 
 
 
 
 
Figure 26 Scheme of miRNA-155-dependent regulation of FcεRI in human LC. TLR-induced or ectopic 
miRNA-155 reduces PU.1 and subsequently FcεRI expression. 
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5 Discussion 
FcεRI is a crucial structure involved in IgE mediated allergic reactions, which is usually 
expressed on mast cells and basophiles. In the context of atopic dermatitis (AD), FcεRI is 
also expressed on epidermal LC and inflammatory dendritic epidermal cells (IDEC) and is 
involved in the pathophysiology of the disease (Bieber, de la Salle et al. 1992, Wollenberg, 
Kraft et al. 1996). Activation of LC by cross-linking of the receptor via allergen bound IgE 
may lead to either inflammatory immune responses via cytokine release and T cell activation 
or may also contribute to regulatory processes. AD skin is highly colonized with 
Staphylococcus aureus (S.a.) (Boguniewicz and Leung 2010) which can be recognized by 
pattern recognition receptors (PRR) like Toll-like receptors (TLR). We have shown 
previously that TLR-mediated activation on in vitro generated LC results in a downregulation 
of FcεRI expression (Herrmann, Koch et al. 2013). However, the mechanism governing the 
expression of FcεRI on LC in the context of AD is still unclear.  
The aim of this work was to study the molecular mechanisms of the regulation of the FcεRI 
expression on human LC. Molecular aspects acting on the regulation of FcεRI expression 
were investigated. 
 
5.1 In vitro generated CD34LC are comparable to skin-derived LC 
CD34LC were generated from CD34+ hematopoietic stem cells. Immature CD34LC express 
high amounts of Langerin and no CD83. TLR2 expression was sufficient for activation of 
CD34LC as shown by elevated surface protein levels of the DC maturation marker CD83. 
Additionally, the chemokine receptor CCR6, representative for immature DC, was 
downregulated while the maturation-associated chemokine receptor CCR7 was upregulated 
upon activation of CD34LC by TLR ligands. Thus, in vitro generated CD34LC are 
comparable to immature skin LC. Advantageously, CD34LC provide sufficient amounts of 
immature LC compared to isolated skin LC which are often restricted first in the number of 
the donors and secondly in the number of isolated LC. Moreover, skin LC often get activated 
by the isolation process and would not be suitable for further investigations in the context of 
this study.  
FcεRI was heterogeneously expressed on the CD34LC. This could be explained by a 
differential donor dependent genetic background like single nucleotide polymorphisms for 
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FcεRI (Potaczek et al. 2009, Weidinger et al. 2010). Additionally, existing diseases, drug 
treatments, certain pregnancy conditions or yet-to-be-defined factors that could not be 
worked out within the scope of the study may contribute to this heterogeneity. However, 
variable FcεRI expression on CD34LC mirrors those of epidermal LC of skin preparations 
from healthy and atopic donors (Jurgens, Wollenberg et al. 1995).  
In summary, in vitro generated CD34LC are comparable to immature skin LC and provide a 
suitable cell model to investigate TLR engagement-dependent FcεRI regulation.  
 
5.2 FcεRI is downregulated by TLR engagement 
CD34LC were stimulated with different TLR ligands as well as with bacterial lysates from 
S.a. and S.p. and FcεRI was downregulated strongly on the transcriptional and on the 
protein level. In contrast, elevated FcεRI expression levels were observed in AD (Bieber, de 
la Salle et al. 1992, Boguniewicz and Leung 2010, Wollenberg, Kraft et al. 1996) in spite of 
S.a. predominance, which would initiate TLR2-mediated responses of LC. Usually, activated 
LC leave the skin and migrate to local lymph nodes. It could be speculated that the high 
FcεRI expression as observed on AD LC is found on those resident skin LC that have not 
yet seen or even did not react to any TLR stimuli for reasons of habituation to the continuity 
of the bacterial attraction. In vitro generated cells were grown without any microbial stimuli 
by working under sterile conditions and therefore retain FcεRI expression. Another reason 
could be single nucleotide polymorphisms (SNP) in the FCER1A promotor region that go 
along with an upregulation of the receptor (Potaczek et al. 2013, Potaczek, Nishiyama et al. 
2009, Weidinger, Gieger et al. 2008) in AD. Unfortunately, the origin of the blood samples 
used in this study did not allow for information about a putative atopic background and/or a 
current immunotherapy of the donors. In monocyte-derived DC, FcεRIα has been reported 
to reach the cell surface in dependency of FcεRIγ, which is expressed predominantly in DC 
from atopic individuals compared to non-atopic ones (Novak et al. 2003). In CD34LC, 
FCER1G mRNA expression levels were comparable to those of FCER1A in unstimulated 
cells, but were downregulated to a lesser extent upon stimulation. Thus, FCER1A seems to 
be the limiting factor of FcεRI surface expression in CD34LC.  
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5.3 Transcription factor PU.1 is involved in the downregulation of FCER1A 
Regulation of FcεRI has been investigated in human mast cells (Inage et al. 2014). The 
transcription factors PU.1, Yy1, Gata-1, Hmgb1, Hmgb2 and Sp1 are described as 
enhancers of the proximal promotor of FCER1A, while Elf-1 represses its transcription by 
competing with PU.1 and Yy1 for the same binding site in the promotor sequence 
(Hasegawa, Nishiyama et al. 2003, Nishiyama, Hasegawa et al. 2002). PU.1 is a key factor 
in hematopoiesis and is highly expressed in lymphoid and myeloid progenitors (Scott et al. 
1997, Scott et al. 1994). Among the transcription factors investigated here, PU.1 was most 
abundantly expressed in CD34LC. Its expression exceeded the mRNA levels of ELF1, YY1, 
HMGB1, HMGB2 and SP1 up to 4-fold. GATA1 was not expressed. The very low expression 
levels of ELF1 were unexpected, because ChIP-chip and co-transfection assays revealed 
PU.1 as a positive upstream regulatory element of the ELF1 promotor (Calero-Nieto et al. 
2010). One explanation could be an impeded ELF1 promotor accessibility for PU.1 or a 
reduced promotor activity in CD34LC. However, the extend of the inhibitory influence of Elf-
1 on the FcεRI expression still remains questionable since ELF1 mRNA was in part reduced 
upon stimulation of the cells, too.  
Stimulation experiments of CD34LC with TLR1/2 and TLR2/6 heterodimer ligands or with 
bacterial lysates of S.a. and S.p. revealed a significant downregulation of the transcription 
factor PU.1 in all cases. YY1, HMGB1 and HMGB2 expression was decreased by all stimuli, 
too. Only SP1 showed little or no effect upon TLR engagement. Analysis of the FCER1A-
associated transcription factors showed a positive correlation between FCER1A expression 
and the transcription factors ELF1, PU.1, YY1, HMGB1 and HMGB2. Taken together, PU.1 
may be the most influencing factor accompanied by Yy1, Hmgb1 and Hmgb2. One should 
keep in mind that the expression of FcεRI could be biased by the location and the 
phosphorylation status of the transcription factor proteins. As already mentioned in the 
introduction, the human FCER1A promotor consists of a proximal promotor cooperating with 
Elf-1, PU.1, Yy1 and Gata-1, while PU.1 and Yy1 have an inhibitory effect on the distal 
promotor element (Hasegawa, Nishiyama et al. 2003). The opposing function of PU.1 and 
Yy1 on the two promotor sites may have no influence in the CD34LC model, since the 
activity of the distal promotor element is IL-4 dependent and CD34LC are generated in the 
absence of IL-4. 
Concerning the human α-chain promotor, there are several known SNP associated with 
allergic diseases and serum IgE levels (Weidinger, Gieger et al. 2008). A strong promotor 
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activation is described for the -315T and -66T allele sequences that allow the binding of 
Hmgb1 and Hmgb2 as well as several Gata-1 molecules. A weaker activity is reported for 
the -315C and the -66C allele sequences promoting Sp1 binding and less Gata-1 binding 
(Kanada, Nakano et al. 2008). Since GATA1 and SP1 transcripts are not accordingly 
expressed very weakly, PU.1 may be in fact the most important factor for the FcεRI 
expression in CD34LC. 
 
5.4 miRNA-155 is sufficient for downregulation of FcεRI via its transcription 
factor PU.1 
FCER1A is only one of at least 3000 genes regulated by PU.1 which is a key factor 
determining hematopoiesis and cell fate (Burda et al. 2010). Its expression is crucial for the 
differentiation and development of several lymphoid and myeloid cell lineages (Iwasaki et al. 
2005, Scott, Fisher et al. 1997, Scott, Simon et al. 1994). PU.1 dysregulation can lead to 
severe leukemic diseases (reviewed in (Turkistany and DeKoter 2011)). Therefore, a precise 
control of PU.1 expression and function is indispensable. 
The PU.1 promotor exhibits binding sites for several transcription factors like Sp1, Gata-1, 
Oct-1 and at least for PU.1 itself (Burda, Laslo et al. 2010). A sufficient and tissue-specific 
PU.1 expression depends on an additional upstream regulatory element (URE). Mouse 
experiments showed a strong decrease of PU.1 expression after deletion of the URE 
(Rosenbauer et al. 2006). The URE itself contains binding sites for several transcription and 
co-factors like C/EBP, Elf-1, Runx-1 or PU.1 itself. Binding of C/EBPα to the URE opens 
downstream chromatin structures for the binding of PU.1. Runx-1 is only required in early 
blood cell development and is not further required in myeloid cells (Leddin, Perrod et al. 
2011). Here, the investigated transcription factors ELF1 and SP1 showed only minor 
expression and in the case of SP1 no regulation upon stimulation of the cells. C/EBPA was 
expressed only negligibly in CD34LC. Because of its very low expression, C/EBPA 
expression differences between unstimulated and stimulated cell should be judged very 
carefully. PU.1 is constitutively expressed highly in CD34LC and is downregulated due to 
TLR engagement. This effect could be due to an altered availability of the promotor, the 
URE binding sites or the phosphorylation status of promotor- or URE-related factors. 
Additionally, PU.1 activity can be influenced by protein-protein interactions with other 
transcription factors like Gata-1, Gata-2 or C/EBPα (Nerlov, Querfurth et al. 2000, Reddy, 
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Iwama et al. 2002). GATA1 and GATA2 mRNA could not be detected in CD34LC and the 
very low expression of C/EBPA transcripts indicated a lack of sufficient protein amounts. 
Therefore it is unlikely that these mechanisms play major roles in TLR-mediated regulation 
of PU.1 in CD34LC.  
Besides its transcriptional regulation, PU.1 protein synthesis can be regulated post-
transcriptionally by binding of miRNA-155 to the 3’ UTR of PU.1 mRNA (Martinez-Nunez, 
Louafi et al. 2009). In CD34LC, miRNA-155 was induced and PU.1 decreased upon TLR 
engagement. The downregulation of PU.1 by miRNA-155 was confirmed by ectopic 
miRNA-155 expression independent of any stimulation. Since miRNA-146a is expressed 
constitutively in human LC and is highly involved in endotoxin-induced tolerance (Nahid, 
Satoh et al. 2011), this miRNA was investigated, too. miRNA-146a is positively controlled by 
NF-κB and PU.1, while C/EBPα is a dominant negative regulator of miRNA-146a (Jurkin, 
Schichl et al. 2010). It targets inter alia TLR down-stream signaling molecules like IRAK1 
(IL-1R-associated kinase-1) and TRAF6 (TNFR-associated factor 6) (Taganov, Boldin et al. 
2006). Keratinocytes and skin of patients with AD show an elevated level of miRNA-146a 
that is assumed to control inflammation by affecting NF-κB dependent inflammatory immune 
responses (Rebane, Runnel et al. 2014). Here, miRNA-146a expression was only little 
affected after stimulation of CD34LC with TLR ligands and ectopic miRNA-146a revealed no 
significant effect on FCER1A, FCER1G, PU.1 or FcεRIα-associated transcription factors. In 
the context of PU.1 dependent regulation of the FcεRI expression in CD34LC, miRNA-146a 
plays no functional role.  
Compared to healthy skin, AD skin exhibits elevated miRNA-155 levels mainly provided by 
dermal infiltrating CD4+CD3+ T and to a lesser extent by DC (Sonkoly, Janson et al. 2010). 
In total AD skin samples, miRNA-155 levels are highest in lesional skin followed by 
perilesional skin and lowest in normal skin (Ma et al. 2015). The results obtained in this 
study would suggest a reduction of PU.1 in the case of miRNA-155 binding, but PU.1 itself 
has been described to be elevated in AD, too (Ma et al. 2014). In PBMC of AD patients PU.1 
mRNA levels correlate with SCORing atopic dermatitis index (SCORAD) and with IgE levels 
(Ma, Xue et al. 2014). In murine bone marrow derived mast cells (BMMC) PU.1 mRNA and 
protein levels are increased upon IL-33 treatment (Ito, Egusa et al. 2015), an interleukin that 
is upregulated upon house dust mice (HDM) or staphylococcal enterotoxin B (SEB) 
exposure (Savinko et al. 2012) in the human disease. In mice, IL-33 is positively regulated 
by miRNA-155 in chronic allergen challenged type 2 innate lymphoid cells (ILC2) 
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(Johansson et al. 2016). This would suggest that miRNA-155-induced PU.1 expression via 
IL-33 is more powerful than a concurrent downregulation of PU.1 through direct 
miRNA-155/mRNA interaction. In CD34LC, IL-33 receptor protein ST2 was not detectable 
on protein and on mRNA levels (personal communication, Tim Stroisch) and IL-33 did 
neither affect PU.1 nor FCER1A or FCER1G expression. 
 
However, in vivo the expression of transcription factors like C/EBPα and Gata-1 as well as 
the IL-33 receptor and IL-33 itself may be different and therefore influence the expression of 
FcεRI in healthy and in the disease. 
 
Post-transcriptionally, alterations in the 3’ UTR of PU.1 may influence target gene 
expression. A functional SNP in the 3’UTR (rs1057233) has been described in peripheral 
blood leukocytes of systemic lupus erythematosus patients and enhances PU.1 transcription 
(Hikami et al. 2011). In silico alignment using CLUSTAL-O (1.2.4) multiple sequence 
alignment (http://www.ebi.ac.uk/Tools/services) revealed no known SNP in the PU.1’s 
3’ UTR (https://www.ncbi.nlm.nih.gov/snp/?term=SPI1) that affects the binding site for 
miRNA-155 (see Figure 27).  
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_site      ---------------CUCCCCGCUGGCCAUAGCAUUAA---------------------- 
rs1057233        ------------------------------------------------------------ 
PU.1 3’UTR       ccggccccgccaggcctccccgctggccatAGCATTAagccctcgcccggcccggacaca 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
 
Figure 27 Up to date, no SNP of PU.1 3’ UTR has been located in the miRNA-155 binding region. PU.1 
3’ UTR SNP sequences taken from https://www.ncbi.nlm.nih.gov/snp/?term=SPI1 were aligned with PU.1 mRNA 
(GenBank: X52056.1) and the miRNA-155 pairing side (http://www.targetscan.org) using CLUSTAL O (1.2.4) 
multiple sequence alignment (http://www.ebi.ac.uk/Tools/services). The representative detail of the binding region 
of miRNA-155 and the PU.1`s 3’ UTR of the alignment is depicted (for complete alignment see attachment 8.1).  
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Moreover, the expression of cell type specific trans-acting factors like mRNA-binding 
proteins (RBP) can influence miRNA binding efficacy (Nam et al. 2014). RBB-induced local 
changes in the mRNA facilitate miRNA binding and function. This mechanism is well 
explained by the p27 tumor suppressor, whose miRNA (miR-221 and miR-222) are able to 
act on the p27 target mRNA only after RBP Pumilio-1 catalyzed local changes (Kedde et al. 
2010, Nam, Rissland et al. 2014).  
In summary, a miRNA-155 overcoming the PU.1 level or alterations of the PU.1’s 3’UTR by 
not yet discovered SNP or RBP may affect the dialogue between miRNA-155 and PU.1 in 
AD.  
 
On behalf of the expression of FcεRIγ and FcεRIα-associated transcription factors, online 
miRNA target prediction tools (http://www.microrna.org, http://www.targetscan.org) did not 
identify conserved binding sites of miRNA-155 nor of miRNA-146a for FCER1G, ELF1, 
HMGB1, HMGB2 and SP1. Only for YY1, a putative binding of miRNA-146a (5p or 3p n/a) 
was found using http://www.microrna.org prediction tool. However, it could not be validated 
with the help of another miRNA target validation tool (http://mirtarbase.mbc.nctu.edu.tw). 
Nevertheless, miRNA-146a transfection showed a slightly, but not significant reduced YY1 
expression and therefore may not have a strong relevance in CD34LC. Despite finding no or 
only one questionable target site in the above mentioned FcεRIα-associated transcription 
factors, their expressions were analyzed after transfection of CD34LC with pre-miRNA-155 
and pre-miRNA-146a. Significant and correlative reductions were achieved only for ELF1, 
HMBG1 and SP1 by ectopic miRNA-155. All three factors were still expressed weakly in 
CD34LC even in unstimulated cells. However, FcεRI regulation is not achieved by one factor 
alone and therefore they all may contribute to its regulation. Compared to pre-miRNA-155, 
ectopic miRNA-146a did not reveal any clear effect on the expression of the transcription 
factors investigated here.  
 
5.5 Conclusion 
In conclusion, PU.1 was downregulated by miRNA-155 in CD34LC. In line with its function 
as a positive transcription factor of FcεRI, PU.1 decrease was accompanied by a reduction 
of FcεRI expression. This supports the thesis of a functional TLR – miRNA-155 – PU.1 -
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FcεRI pathway in CD34LC. In AD, this pathway may be altered or interrupted at different 
points. First, TLR expression, susceptibility or activation can be impaired in resident 
epidermal LC. Secondly, miRNA-155 – dependent PU.1 binding and regulation could be 
impaired by a failed miRNA/mRNA pairing or may be overcome by a superior number of 
PU.1 molecules. Thirdly, SNP in the FCER1A promotor may cause a constitutively high 
expression of the receptor. Even if miRNA-155, PU.1 and FcεRI have all been described to 
be elevated in AD, it does not mean that this happens at same time and even not in the 
same cells. Nevertheless, it is very likely that the high expression of FcεRI in the disease is 
regulated rather multifactorially and very individually. This keeps the research in this field 
challenging and very exciting. 
 
5.6 Perspectives 
The observations made in this study revealed the involvement of miRNA-155, the 
transcription factor PU.1 and TLR2/TLR4 in the regulation of FcεRI in human primary LC.  
These findings open new questions concerning differences in the local expression in vivo of 
PU.1 and miRNA-155 between epidermal and mucosal LC, the influence of different 
environmental conditions like UV exposure, pH values, temperatures or the connection to 
other regulatory pathways involved in the regulation of FcεRI. Moreover, the investigation of 
miRNA expression profiles of acute and chronic AD episodes may provide new biomarkers 
for the disease and may open new possibilities for the development of individual treatment 
strategies.  
During the last decade, miRNA therapeutics formulated as anti-miRNA or as miRNA mimics 
have evolved as candidates in the drug development. However, even though there are first 
promising results of preclinical studies (reviewed in (Rupaimoole and Slack 2017)), 
successful application of miRNA as therapeutics is very challenging. In general, miRNA 
target several mRNA, which can be involved in physiological, but also in pathological 
pathways. The involvement of miRNA-155 in lymphoma and solid tumors makes miRNA-155 
a candidate tool for the treatment of those diseases. While studies with anti-miR-155 are 
promising, miRNA-155 mimicking drugs might be problematic, because of the oncogenic 
nature of this special miRNA. Provided that oncogenicity, toxicity and off-target effects will 
be eliminated and an efficacious delivery system can be established, a local low-dose 
treatment with miRNA-155 mimic might drive skin LC to downregulate FcεRI and might thus 
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diminishing inflammatory responses in AD skin. Finally, further tests could verify whether 
combinations of miRNA-155 mimics and established drugs facilitate the therapeutic success.  
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6 Summary 
Atopic dermatitis (AD) is a multifactorial severe skin disease with increasing incidence in 
western countries. In the disease, Langerhans cells (LC) play a pivotal role in bridging 
innate and adaptive immunity through sensing invading pathogens by pattern recognition 
receptors (PRR) like Toll-like receptors (TLR) and presenting them to naïve T cells. A 
hallmark of skin LC of atopic individuals is the expression of the high-affinity receptor for 
IgE, FcεRI. Our former studies revealed that TLR mediated activation of LC results in a 
downregulation of FcεRI expression (Herrmann, Koch et al. 2013), thus influencing the 
course of AD by a cross-talk of those receptors.  
The aim of this study was to shed light on the regulatory mechanisms involved in FcεRI 
expression on activated human LC. Therefore, CD34+ hematopoietic stem cell-derived LC 
(CD34LC) were used for stimulation assays with TLR ligands as well as with heat-killed 
Staphylococcus aureus (S.a.) and Streptococcus pyogenes (S.p.) to mimic the pathogens 
and the commensals colonizing human skin. Stimulation of CD34LC with all ligands resulted 
in a significant downregulation of FcεRI. Analysis of the factors promoting the expression of 
FcεRI revealed that the main transcription factor PU.1 and the less expressed transcription 
factors Yy1, Elf-1, Hmgb1 and Hmgb2 were significantly downregulated upon activation of 
the cells with the ligands used here.  
Since PU.1 was the strongest expressed transcription factor in CD34LC, its regulation was 
further investigated. PU.1 is inter alia controlled by micro-RNA-155 (miRNA-155), a miRNA 
that is induced in macrophages and DC upon activation. The expression of miRNA-155 was 
examined and, additionally, CD34LC were transfected with pre-miRNA-155 molecules to 
confirm the effect of those miRNA on the expression of FcεRI. In summary, a high induction 
of miRNA-155 was observed under all stimulation conditions followed by a decrease of 
PU.1, which was further confirmed by ectopic miRNA-155. In line with PU.1 downregulation, 
FcεRI expression also decreased with all stimuli and with ectopic miRNA-155, too. 
Another important immunological miRNA is miRNA-146a, which is expressed constitutively 
on LC and facilitates endotoxin-induced tolerance. miRNA-146a analysis was included in 
this study to check a putative involvement of this miRNA in the regulation of FcεRI 
expression. In contrast to miRNA-155, miRNA-146a was only weakly induced upon 
stimulation of CD34LC. Additionally, no effect of ectopic miRNA-146a on FcεRI expression 
was detected.  
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In conclusion, the results of this thesis revealed a regulatory network between TLR and 
FcεRI involving the TLR-dependent induction of miRNA-155, which in turn controls the 
translation of PU.1 and in succession the expression of FcεRI. 
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9 Attachment 
9.1 Multiple sequence alignment of SNP in PU.1 mRNA with miRNA-155 
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1 mRNA        gtagctcagggggcaggcctgagccctgcacccgccccacgaccgtccagcccctgacgg 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gcaccccatcctgaggggctctgcattggcccccaccgaggcaggggatctgaccgactc 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             ggagcccggctggatgttacaggcgtgcaaaatggaagggtttcccctcgtcccccctcc 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
104 Attachment 
PU.1             atcagaagacctggtgccctatgacacggatctataccaacgccaaacgcacgagtatta 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             cccctatctcagcagtgatggggagagccatagcgaccattactgggacttccaccccca 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             ccacgtgcacagcgagttcgagagcttcgccgagaacaacttcacggagctccagagcgt 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gcagcccccgcagctgcagcagctctaccgccacatggagctggagcagatgcacgtcct 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
Attachment  105 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             cgatacccccatggtgccaccccatcccagtcttggccaccaggtctcctacctgccccg 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ----------------------------------------------------------CG 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gatgtgcctccagtacccatccctgtccccagcccagcccagctcagatgaggaggaggg 
rs528011574      ------------------------------------------G----------------- 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          G-----------------GTCGTCCTCTGCAAGGTTGCCCCGG----------------- 
rs371396849      --------------------------------------CCCGG----------------- 
rs562299021      ----------------------------GCAAGGTTGCCCCGG----------------- 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             cgagcggcagagccccccactggaggtgtctgacggcgaggcggatggcctggagcccgg 
rs528011574      -----------------------CGGGATGTGGAGGGGGCCTGGAGTCGGGGGAGGGGGC 
rs878963605      ----------------------------TGTGGAGGGGGCCTGGAGTGGGGGGAGGGGGC 
rs878892082      ----------------------------------GGGGGCCTGGAGTGGGGGGAGGGGGC 
rs764782105      -------------------------------GACGCCCAGCTGGCGTCCGGGAGCCGGGG 
rs10747          -----------------------TGGGGTCTGACGCCCAGCTGGCG-------------- 
rs371396849      -----------------------TGGGGTCTGACGCCCAGCTGCCGTCCGGGAGCCGGGG 
rs562299021      -----------------------TGGGGTCTGACGCCCAGCTGGCGTCCGGGAGCCGGG- 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gcctgggctcctgcctggggagacaggcagcaagaagaagatccgcctgtaccagttcct 
rs528011574      GGGTGAGGCGAGG----------------------------------------------- 
rs878963605      GGGTGAGGCGAGGCCCGGC----------------------------------------- 
rs878892082      GGGTGAGGCGAGGCCCGGCCCGCCA----------------------------------- 
rs764782105      TGGAGTCCTGGAGGGAGGCGAA-------------------------------------- 
rs10747          ------------------------------------------------------------ 
rs371396849      TGGAGTCCT--------------------------------------------------- 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
106 Attachment 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ----------------AGGGGAGATCT--------------------------------- 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gttggacctgctccgcagcggcgacatgaaggacagcatctggtgggtggacaaggacaa 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gggcaccttccagttctcgtccaagcacaaggaggcgctggcgcaccgctggggcatcca 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      --------------------TGTGCTGCAAGAGGATGGATTG------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gaagggcaaccgcaagaagatgacctaccagaagatggcgcgcgcgctgcgcaactacgg 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      --------------------------AGAATAACTTTACTTGTTTTTTGGGAGGA----- 
rs182746140      -----------------------------ATAACTTTACTTGTTTTTTGGGAGGA-GGTT 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             caagacgggcgaggtcaagaaggtgaagaagaagctcacctaccagttcagcggcgaagt 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
Attachment  107 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      AATGGGTGGGAGGGGTGAGAG--------------------------------------- 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gctgggccgcgggggcctggccgagcggcgccacccgccccactgagcccgcagcccccg 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ------------------------------------------------------------ 
mir155_side      ---------------CUCCCCGCUGGCCAUAGCAUUAA---------------------- 
rs1057233        ------------------------------------------------------------ 
PU.1 3’UTR       ccggccccgccaggcctccccgctggccatAGCATTAagccctcgcccggcccggacaca 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        ---------------------------AGGACTGTGGCGGGCCGGGCCTCGCCTCACCCG 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             gggaggacgctcccggggcccagaggcaggactgtggcgggccgggctccgtcacccgcc 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ------------------------------------------------------------ 
rs1057221        CCCCCTCCCCCCACTCCA------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             c---ctccccccactccaggccccctccacatcccgcttcgcctccctccaggactccac 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
108 Attachment 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      -------------------------------------------------------GATTT 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ------------------------------------------------------------ 
PU.1             cccggctcccgacgccagctgggcgtcagacccaccggcaaccttgcagaggacgacccg 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ------------------------------------------------------------ 
rs182746140      ------------------------------------------------------------ 
rs531943594      ACATACGGACTTGAGACTCCCAAGGCAGTACCCCG------------------------- 
rs1057221        ------------------------------------------------------------ 
mir155_side      ------------------------------------------------------------ 
rs1057233        ---------------------------------------------CCCTCTCACCCCTCC 
PU.1             gggtactgccttgggagtctcaagtccgtatgtaaatcagatctcccctctcacccctcc 
rs528011574      ------------------------------------------------------------ 
rs878963605      ------------------------------------------------------------ 
rs878892082      ------------------------------------------------------------ 
rs764782105      ------------------------------------------------------------ 
rs10747          ------------------------------------------------------------ 
rs371396849      ------------------------------------------------------------ 
rs562299021      ------------------------------------------------------------ 
                                                                              
 
rs116330587      ----------------------------------------------- 
rs182746140      ----------------------------------------------- 
rs531943594      ----------------------------------------------- 
rs1057221        ----------------------------------------------- 
mir155_side      ----------------------------------------------- 
rs1057233        CACCCATTAACCTCCTCCCAAAAAACAAGTAAAGTT----------- 
PU.1             cacccattaacctcctcccaaaaaacaagtaaagttattctcaatcc 
rs528011574      ----------------------------------------------- 
rs878963605      ----------------------------------------------- 
rs878892082      ----------------------------------------------- 
rs764782105      ----------------------------------------------- 
rs10747          ----------------------------------------------- 
rs371396849      ----------------------------------------------- 
rs562299021      ----------------------------------------------- 
 
 
Figure S1: No described SNP of PU.1 3’ UTR is located in the miRNA-155 binding region. PU.1 3’ UTR 
SNP sequences taken from http://www.ebi.ac.uk/Tools/services were aligned with PU.1 mRNA (GenBank: 
X52056.1) and the miRNA-155 pairing side (http://www.targetscan.org) using CLUSTAL O (1.2.4) multiple 
sequence alignment (http://www.ebi.ac.uk/Tools/services). 
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